NOVEL POLYPEPTIDES

Abstract: The present invention relates to variants of Penicillin Binding Proteins (PBP), which proteins are involved in bacterial peptidoglycan biosynthesis. Disclosed are also DNA molecules coding for the said PBP variants, as well as vectors and cells harbouring such DNA molecules. The invention is also related to processes for assaying and designing therapeutically useful compounds which have high affinity to PBP, which processes utilize the said PBP variants.

Description: /16082 _ ! _ NOVEL POLYPEPTIDES TECHNICAL HELD The present invention relates to variants of Penicillin Binding Proteins (PBP), which proteins are involved in bacterial peptidoglycan biosynthesis. Disclosed are also DNA molecules coding for the said PBP variants, as well as vectors and cells harbouring such DNA molecules. The invention is also related to processes for assaying and designing therapeutically useful compounds which have high affinity to PBP, which processes utilize the said PBP variants. BACKGROUND ART Bacteria and most other unicellular organisms possess a cell wall, which comprises a cross-linked polysaccharide-peptide complex called peptidoglycan. Peptidoglycan biosynthesis consists of three stages: (1) synthesis of precursors (sugar nucleotides) in the cytosol, (2) precursor transfer across the membrane and formation of the polysaccharide chain, and (3) cross-linking of individual peptidoglycan strands in the cell wall. In the latter stage of peptidoglycan biosynthesis, new bonds must be made between nascent glycan strands and existing peptidoglycan. The newly synthesized chains are about 10 disaccharides long and are extended by transglycosylase enzymes to a final glycan strand of between 100 and 150 disaccharide units. The peptidoglycan is crosslinked by the action of transpeptidases which link the terminal D-ala of one glycan strand to a free ε-amino group on a diaminopimelic acid residue on an adjacent region. A number of antibiotics inhibit bacterial growth by interfering with the formation of the peptidoglycan layer. The cross-linking reaction is the target for action of two important classes of such antibiotics, the penicillins and the cephalosporins. Penicillin is thought to react irreversibly with the transpeptidase that catalyses cross-linking. The penicillin interactive proteins fall into three groups: the β-lactamases, the Low Molecular Weight-Penicillin Binding Proteins (PBPs), which mainly include the carboxypeptidases, and the High Molecular Weight- Penicillin Binding Proteins. Penicillin Binding Proteins are those enzymes which have been shown to bind radiolabelled penicillin G. In Escherichia coli such proteins are called e.g. PBP 1A and PBP IB, both belonging to the class High Molecular Weight-PBPs. PBP 1A and IB, which are known to be membrane bound proteins, maintain cell integrity and control peptidoglycan side wall extension during growth. Inactivation of either PBP 1A or PBP IB can be tolerated by the bacteria while the deletion of both the genes, designated ponA and pon , is lethal (Yousif et al., 1985). PBP IB is known to be a bifunctional enzyme possessing both transpeptidase and transglycosylase activity (Ishino et al., 1980). PBP 1A is believed to be bifunctional since it can substitute for PBP IB. The β-lactam antibiotics, such as penicillin, inhibit only the transpeptidase activity of these proteins. The transglycosylase reaction is inhibited by e.g. moenomycin, which is a phosphoglycolipid used as a growth promoter in animal nutrition and which has been shown to possess broad spectrum bactericidal activity. The enzyme transglycosylase has been shown to be present in Escherichia coli, Staphylococcus aureus, Bacillus megaterium and Bacillus subtilis. This suggests that interference of peptidoglycan biosynthesis by inhibition of transglycosylase could be a lethal event in all clinically important pathogens. The putative transglycosylase domain of PBP IB has been assigned to the N-terminal 478 amino acids (Nakagawa et al., 1987). This regions includes three conserved stretches of amino acids between the N-terminal half of both PBP 1A and IB and could represent residues involved in the transglycosylase activity. Preparation of Penicillin Binding Protein 2A from Staphylococcus aureus is disclosed in EP-A-0505151. DISCLOSURE OF THE INVENTION There is a growing number of reports of bacteria which are resistant to antibiotics. There is consequently a need for new compounds which inhibit bacterial growth by means of binding Penicillin Binding Proteins. The present invention provides PBP variants which facilitate processes for assaying and designing therapeutically useful compounds which have high affinity to PBPs. Accordingly, it is an object of the invention to provide polypeptides which are water-soluble active derivatives of bacterial bifunctional Penicillin Binding Proteins, said Penicillin Binding Proteins being bound to the cell membrane when expressed in a bacterial cell and being capable of exhibiting both transglycosylase and transpeptidase activities and said derivatives lacking a membrane anchoring sequence but retaining the capability to exhibit one or both of said enzymic activities. The "bacterial cell" mentioned above is preferably an Escherichia coli cell or a Streptococcus pneumoniae cell. The soluble PBP variants according to the invention retains transglycosylase activity, indicating that soluble variants of PBP, devoid of membrane anchoring sequences, can recognize lipid linked substrate and polymerise the disaccharide into repeating units. It can thus be assumed that other analogues of PBP lacking residues involved in membrane attachment would be enzymatically functional. Molecules interacting with the penicillin interactive region of soluble PBP variants could be assumed to be capable of interacting identically with wild-type PBPs. Consequently, the soluble PBP variants according to the invention can be used for identifying compounds which are interacting with wild-type Penicillin Binding Proteins. It is furthermore well known that membrane-bound proteins are very difficult to crystallize. The soluble enzymatically active PBP variants can be used for crystallisation and will thereby facilitate a rational design, based on X-ray crystallography, of therapeutic compounds inhibiting High Molecular Weight-PBPs. A further object of the invention is to provide polypeptides which are truncated water-soluble derivatives of bacterial bifunctional Penicillin Binding Proteins, said Penicillin Binding Proteins being bound to the cell membrane when expressed in a bacterial cell and being capable of exhibiting both transglycosylase and transpeptidase activities and said derivatives lacking the membrane anchoring sequence but retaining the capability to exhibit the transglycosylase activity. The "bacterial cell" mentioned above is preferably an Escherichia coli cell. Alignment of amino acid sequences of High Molecular Weight-Penicillin Binding Proteins, and the compilation of the motifs involved in the penicillin binding of β-lactamases and carboxypeptidase, have suggested the C-terminal half of PBP 1A and IB to be the functional domain of the transpeptidase activity and includes the penicillin binding domain. In addition, Nakagawa et al. (1987) showed that a truncated ponB gene encoding the N-terminal 478 amino acids of PBP IB is capable of the transglycosylase reaction. On the basis of these findings, it has been suggested that the high molecular weight PBP 1A and IB proteins are two domain-proteins, with the N-terminal half forming the transglycosylase domain and the C-terminal half the transpeptidase domain. The two domains have been predicted by computer analysis to be joined by a linker or hinge region which does not structurally or enzymatically contribute to the function of the protein. The linker region of E.coli PBP IB has been predicted to be from position 545-559 while that for E.coli PBP 1A around position 501. The monofunctional truncated variants of PBP according to the invention will, when used in x-ray crystallography, facilitate obtaining structural information of the transglycosylase domain of penicillin binding proteins. In addition, the reduced size of the monofunctional variant will facilitate crystallization. In a preferred form, a water-soluble polypeptide according to the invention has an amino acid sequence which is identical to SEQ ID NO: 2, 4, 6, 12 or 13 in the Sequence Listing. The observation that deletion of the po A and ponB genes is lethal (Yousif et al., 1985) does not address the question of essentiality of the transglycosylase activity of the encoded PBP 1A proteins, since the deletion results in the loss of both transglycosylation and transpeptidation activities. In addition, this experiment does not address the possibility that the transglycosylase enzyme activity can be contributed by a Penicillin Binding Protein other than PBP 1A or PBP IB. It is also possible that hitherto undescribed Penicillin Binding Proteins and /or other proteins that contribute to the transglycosylase activity exist. Alignment of the amino acids forming the putative transglycosylase domain of PBP 1A and IB reveals three stretches of 9 out of 12 (Region 1), 9/10 (Region 2) and 8/10 (Region 3) amino acids identical within the N-terminal half of these two proteins (Broome-Smith et al., 1985) (Fig. 14). The same 3 regions are identically conserved among two other recently described protein sequences; Streptococcus pneumoniae PBP 1A (Martin et al., 1992) and a 94 kDa protein from Haemophilus influenzae (Tomb et al., 1991). The conservation of these residues in such diverse species suggests their critical requirement in either maintaining structural aspects of the protein, or in the transglycosylation reaction itself. The overlapping functional transglycosylase and transpeptidase activities of PBP 1A and IB also suggests conservation of the catalytic centres and that molecules designed to interact with the catalytic centre of PBP 1A would be reactive also with PBP IB. The functional transglycosylase activity of the expressed protein can be studied either in a direct in vitro assay using appropriate substrates, or in an assay measuring the ability of the protein to complement the deletion of the corresponding genes in the chromosome. It has been shown that a plasmid with a gene encoding the wild type product (PBP 1A or PBP IB) is capable of maintaining the viability of the E.coli cell (Yousif et al., 1985). This trans-complementation technique can be utilized to assess the functional nature of the mutant gene(s) encoding PBPs with mutations inactivating one of the enzymic (transglycosylation or transpeptidation) functions. The ability of such mutant products to complement in trans the deletion of the chromosomal ponA and pon genes would define the essential requirement of the individual enzymic functions. There is consequently a need for research tools which will make it possible to study the effects of specific inactivation of the transglycosylase activity of Penicillin Binding Proteins. Consequently, a further aspect of the invention is a polypeptide which is a transglycosylase deficient derivative of a bacterial bifunctional penicillin binding protein, said penicillin binding protein being bound to the cell membrane when expressed in a bacterial cell and being capable of exhibiting both transglycosylase and transpeptidase activities and said derivative lacking the capability to exhibit transglycosylase activity but retaining the capability to exhibit transpeptidase activity. The "bacterial cell" mentioned above is preferably an Escherichia coli cell. The transglycosylase deficient PBP variants can advantageously be used in X-ray crystallography for the purpose of obtaining structural information of the activity sites of PBPs. Structural analysis of crystal form of soluble transglycosylase deficient PBP variants could allow delineation of the catalytic region and facilitate the design of molecules capable of specifically inhibiting the transglycosylase activity. In a preferred form, the transglycosylase deficient polypeptide according to invention is a polypeptide which is lacking transglycosylase activity because of a mutation or deletion in the second conserved region of the gene coding for said polypeptide. In a further preferred form, the transglycosylase deficient polypeptide according to the invention has an amino acid sequence which is identical to SEQ ID NO: 7, 8, 9, or 10 in the Sequence Listing. The conventional purification procedure employed for the enrichment of penicillin binding proteins has been the use of a "penicillin" affinity. The binding of the protein to penicillin is covalent and requires harsh conditions to elute the bound protein. This may lead to a certain degree of inactivation of the enzymic activity of the protein. There is consequently a need for alternate affinity matrices for the efficient purification of the proteins. Included in the invention is consequently a polypeptide comprising (a) a first polypeptide which is a PBP variant according to the invention; and (b) an additional polypeptide which allows binding to an affinity matrix; there being a cleavage site between said polypeptides. The "additional polypeptide" mentioned above can preferably be glutathione-S-transferase or a polypeptide substantially similar to glutathione-S-transferase. Such an additional polypeptide will enable rapid purification of the protein using Glutathione Sepharose affinity matrix. In another preferred form, the additional polypeptide is a polypeptide rich in histidine residues, which residues will confer on the protein the ability to bind to an Ni affinity column. The additional polypeptide can be fused either to the N-terminus or the C-terminus of the soluble/membrane bound PBP. The ability of the fusion proteins to bind to an affinity matrix allows immobilisation of the protein. Such immobilised proteins can be used for analysis of competitive binding of different ligands to the bound active protein, and thus for screening of compounds binding to the enzymic domain of interest. The polypeptides according to the invention are not to be limited strictly to any one of the sequences shown in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biochemical activities of the PBP variants which amino acid sequence is disclosed in the Sequence Listing. Included in the invention are consequently also polypeptides, the amino acid sequence of which is at least 90% homologous, preferably at least 95% homologous, with the amino acid sequence of any of the PBP variants according to the invention. 16082 _g_ PCIYSE9 A further object of the invention is to provide isolated and purified DNA molecules which have nucleotide sequences coding for any one of the PBP variants according to the invention. In a preferred form of the invention, the said DNA molecules have nucleotide sequences identical to SEQ ID NO: 1, 3 or 5 in the Sequence Listing. However, the DNA molecules according to the invention are not to be limited strictly to any of the sequences shown in the Sequence Listing. Rather the invention encompasses DNA molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the biochemical activities of the PBP variants according to the invention. Included in the invention is also a DNA molecule which nucleotide sequence is degenerate, because of the genetic code, to the said nucleotide sequence coding for a PBP variant according to the invention. The natural degeneracy of the genetic code is well known in the art. It will thus be appreciated that the DNA sequences shown in the Sequence Listing are only examples within a large but definite group of DNA sequences which will encode the PBP variants which amino acid sequences are shown in the Sequence Listing. A further aspect of the invention is a replicable expression vector which carries and is capable of mediating the expression of a DNA molecule according to the invention. In the present context the term "replicable" means that the vector is able to replicate in a given type of host cell into which is has been introduced. Examples of vectors are viruses such as bacteriophages, cosmids, plasmids and other recombination vectors. Nucleic acid molecules are inserted into vector genomes by methods well known in the art. A vector according to the invention can preferably be one of the plasmids listed in Table 1 below. Included in the invention is also a host cell harbouring a vector according to the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial, yeast or mammalian cell. The methods employed to effect introduction of the vector into the host cell are well- known to a person familiar with recombinant DNA methods. A further aspect of the invention is a process for production of a polypeptide which is a derivative of penicillin binding protein, comprising growing a host cell according to the invention in or on a culture medium for expression of the polypeptide and optionally recovering the polypeptide. An appropriate host cell may be any of the cell types mentioned above, and the medium used to grow the cells may be any conventional medium suitable for the purpose. The High Molecular Weight-Penicillin Binding Proteins have been shown to be anchored to the membrane, but the majority of the protein is within the periplasmic space of the cell (Edelman et al. 1987). Thus PBP derivatives, devoid of the membrane signal / anchoring sequences, are forced to fold into their native state in a heterologous environment, namely the cytosol. This often leads to misfolding, and the majority of the expressed protein aggregates into an inactive form referred to as inclusion bodies. It has now surprisingly been found that high yields of an active water- soluble PBP variant can be obtained by regulated transcription of the gene encoding the said PBP variant. Such regulated transcription involves (i) using a suboptimal concentration of the inducer isopropyl thiogalactoside (IPTG); and (ii) culturing the cells expressing the PBP variant at reduced temperature. A cumulative effect of these factors contributes to the overall recovery of the active soluble protein. Consequently, lower rates of expression, achieved through the mentioned combination of (i) sub-optimal de-repression of promoter systems and (ii) increased generation time by lowering of the temperature of cultivation, will enhance the solubility of proteins lacking the membrane anchoring segment. A further important aspect of the invention is a process for the production of a water soluble polypeptide according to the invention which comprises culturing Escherichia coli cells harbouring an expression vector wherein a DNA coding sequence for said polypeptide is under the control of an isopropyl thiogalactoside (IPTG) - inducible promoter, said culturing being carried out in the presence of a sub-optimal concentration of IPTG for induction of the said promoter and at a temperature in the range of 20 to 24°C, preferably 22°C. The concentration of IPTG can preferably be approximately 0.01 mM. In the case of expression of pon Adel23, a gene encoding a PBP variant according to the invention, such regulated transcription by (i) controlled de-repression of the T7 promoter by using sub-optimal concentration of the inducer IPTG and (ii) reducing the growth rate by culturing at 22°C, resulted in yields of the active protein which reached nearly 50% of the total induced protein of interest. The growth and induction conditions were critical for the efficient recovery of the soluble protein, as growth at higher temperatures or induction with higher concentrations of IPTG resulted in the majority of the protein becoming inactive and forming inclusion bodies. I will be appreciated that this method for controlled expression is applicable to other inducible promoter systems, e.g. the tac system, where the inducer is IPTG and the host is a lac Y negative host. A route to obtain relevant structural information on the active site configuration of an enzyme is the production and characterisation of monoclonal antibodies capable of inhibiting the enzymic reaction. The antibodies inhibiting the activity represent molecules which block or compete with the substrate for entry into the active site pocket, or can represent molecules which can prevent structural transitions required for catalytic activity. In either case, these antibodies can be used as a tool to quantitate interaction of the target enzyme with binding of radiolabelled inhibitory compounds to judge the affinity of interaction provided the affinity of the inhibiting antibody is known. A further use of mapping the epitopes recognised by the inhibitory antibodies is the ability to delineate residues forming the active site. Consequently, a further aspect of the invention is a method of identifying an antibody capable of binding a bacterial bifunctional penicillin binding protein which includes the step of employing a polypeptide according to the invention in an antibody binding assay and selecting antibodies that bind to the polypeptide. Also included in the invention are monoclonal antibodies directed to a PBP variant according to the invention. Such a monoclonal antibody is prepared using known hybridoma technology by fusing antibody-producing B-cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Another aspect of the invention is a method of assaying for compounds which bind to a penicillin binding protein, said method comprising (a) contacting a polypeptide which is a PBP variant according to the invention with a compound to be investigated; and (b) detecting whether said compound binds to the said PBP variant. For example, a method of assaying for compounds which bind to a penicillin binding protein can comprise (a) culturing host cells according to the invention; (b) lysing the said cells and isolating the crude cell extract; (c) exposing the said cell extract to potential inhibitors of a penicillin binding protein; (d) introducing an agent, known to bind a penicillin binding protein, to the said cell extract; (e) removing the unbound fraction of said agent; and (0 assaying the presence of said agent remaining in the cell extract. Another method of assaying for compounds which bind to a penicillin binding protein could comprise (a) exposing a polypeptide which is a PBP variant according to the invention, immobilised on a solid support, to a potential inhibitor of a penicillin binding protein; (b) exposing an agent, known to bind a penicillin binding protein, to the immobilised polypeptide; (c) removing the unbound fraction of said agent; and (d) assaying the presence of said agent bound to the immobilised polypeptide. In a preferred form, the said method is a method of assaying for compounds which bind to the transglycosylase domain of a penicillin binding protein, said method comprising (a) exposing the transglycosylase domain of a polypeptide according to the invention, with the proviso that the polypeptide is not a transglycosylase deficient PBP variant, said polypeptide being immobilised on a solid support, to a potential inhibitor of the transglycosylase activity of a penicillin binding protein; (b) exposing an agent, known to bind the transglycosylase domain of a penicillin binding protein, to the immobilised polypeptide; (c) removing the unbound fraction of said agent; and (d) assaying the presence of said agent bound to the immobilised polypeptide. Antibodies specific for transpeptidase can be immobilised on a BIAcore sensor chip surface. The BIAcore system, wherein "BIA" stands for "Biospecific Interaction Analysis", is available from Pharmacia Biosensor, Sweden. Protein binding to the immobilised antibody is detected by the output RU-signal. Screening for TP inhibitors will be possible by a competitive assay wherein soluble protein is preincubated with test compounds. Binding of a test compound to the protein will result in a decrease in protein binding to TP specific antibody. In the same way, monoclonal antibodies specific for transglycosylase can be used in screening for TG inhibitors. In a similar way, ampicillin or modified moenomycin can be coupled to the surface and used in an indirect competitive assay whereby protein is preincubated with test ligand prior to introduction in the BIAcore. Consequently, yet another method of assaying for compounds which bind to a penicillin binding protein could comprise (a) exposing a polypeptide which is a PBP variant according to the invention to a potential inhibitor of a penicillin binding protein; (b) exposing the polypeptide to an agent, known to bind a penicillin binding protein, which agent is immobilised on a solid support; and (c) assaying the presence of polypeptide bound to the immobilised agent. In a preferred form, the said method is a method of assaying for compounds which bind to the transglycosylase domain of a penicillin binding protein, said method comprising (a) exposing the transglycosylase domain of a polypeptide according to the invention, with the proviso that the polypeptide is not a transglycosylase deficient PBP variant, to a potential inhibitor of a penicillin binding protein; (b) exposing the said polypeptide to an agent, known to bind to the transglycosylase domain of a penicillin binding protein, which agent is immobilised on a solid support; and (c) assaying the presence of polypeptide bound to the immobilised agent. The "agent known to bind a penicillin binding protein" referred to above can e.g. be a monoclonal antibody or a labelled antibiotic compound such as [ 3 H]ampicillin. A further aspect of the invention is a method of determining the protein structure of a penicillin binding protein, characterized in that a polypeptide which is a PBP variant according to the invention is utilized in X-ray crystallography. Some of the features of the preferred PBP variants according to the invention are summarised in Table 1 below. The plasmids listed in the Table have been deposited under the Budapest Treaty at the National Collection of Industrial and Marine Bacteria Limited (NCIMB), Aberdeen, Scotland, UK. The date of deposit is 28 June 1994. TABLE 1 EXAMPLES OF THE INVENTION In the following examples, the terms "standard protocols" and "standard procedures" are to be understood as protocols and procedures found in an ordinary laboratory manual such as the one by Sambrook, Fritsch and Maniatis (1989). EXAMPLE 1 1.1. Construction of gene encoding soluble form of E.coli PBP 1A The possible amino add residues involved in the membrane anchoring region of PBP 1A was deduced following the computer program described by Kyte & Dolittle (1982). The predicted hydrophobicity of the N-terminal 60 amino add is shown in Fig. 1. Based on this hydrophobidty profile, it was predicted that the N-terminal 23 amino adds were strongly implicated to contribute to the membrane anchoring domain of the protein, but may not entirely encompass the membrane anchoring domain. This region was then putatively designated as the region involved in "membrane anchoring". The plasmid pBS98, harbouring the native ponA gene (encoding wild type PBP 1A), was obtained from Prof. B.S. Spratt, Microbial Genetics Group, School of Biological Sciences, University of Sussex, Brighton, UK. The construction of pBS98 is described in Broome-Smith et al. (1985). Plasmid DNA from cells harbouring pBS98 was made following standard protocols. Oligonudeotide primers for use in the polymerase chain reaction (PCR) were synthesized in Applied Biosystems Model 380 A. The 5'- oligonucleotide primer used w?s TG-82: Ncol i 5'-TCG ACC ATG GGC CTA TAC CGC TAC ATC G-3' M G L Y R Y I 23 24 25 26 27 28 29 (Amino acid No. TG-82 incorporates the following characteristics: (1) it allows construction of mutant ponA gene whose encoded product would have the 24 th amino add (glydne) of the wild type PBP 1A as the second amino acid of the expressed mutant protein; and (2) it introduces DNA sequences recognized by the restriction enzyme Ncol. This introduces the codon ATG which corresponds to the first amino add of the mutant PBP 1A when expressed in suitable systems. The 3'-oligonucleotide primer used was TG-64: 5' -CGC GGA TCC GAA TCA CAA CAA TTC CTG TGC-3 t BamKI TG-64 has the following characteristics: (1) it introduces a termination codon following the 850th amino acid of the structural protein of PBP 1A; (2) it introduces a site for the restriction enzyme BtimHI to facilitate cloning into suitable expression vectors. Using these primers, PCR was carried out using pBS98 DNA as template following standard protocols. A DNA fragment of approximately 2.5 kb was amplified. The fragment was digested with the restriction enzyme Ncol followed by digestion with BαmHI. This 2.5 kb Ncol - Bαmrll DNA fragment was then ligated to the vector pBR329 (Covarrubias et al., 1982) previously cut with Ncol and BαmHI. Ligation of the two DNA fragments were carried out using standard protocols and the ligation mixture transformed into E.coli DH 5α. The transformed cells were plated on LB agar plates with 50 μg/ml ampidllin. Following overnight incubation at 37°C, individual ampidllin resistant colonies were tested for their tetracydine sensitivity as insertion into the Ncol - BαmHI region renders the plasmid chloramphenicol and tetracydine sensitive. A recombinant plasmid bearing the 2.5 kb insert was designated pARC0488. The Ncol - BαmHI 2.5 kb DNA fragment was released from pARC0488 and ligated to Ncol - BαmHI cleaved and purified pARC038 (Fig. 2). The plasmid pARC038 is a derivative of pETlld (Studier et al., 1990) in which the EcoRI and Pstl sites were made blunt ended with T4 exonudease and the EcoRI - Pstl 0.75 kb DNA fragment replaced with a blunt ended kanamydn resistance cartridge (Pharmacia Biochemicals). The ligation mixture was transformed into competent cells of E.coli BL 26 (DE3). The transformation mix was plated on LB agar with 50 μg/ml kanamydn. Mini-prep plasmid DNA was made from several kanamydn resistant colonies and screened by restriction endonuclease mapping using standard procedures. One of the colonies harbouring plasmid with expected structure (Fig. 3) was labelled pARC0558 (NCIMB 40666). The DNA sequence of the mutant ponA gene labelled as poπAdel23 is shown as SEQ ID NO: 1. The amino add sequence of the soluble PBP lAdel23 is shown as SEQ ID NO: 2. 1.2. Expression of rwιAdel23 Exoli BL 26 (DE3) cells (obtained from Dr. J.J. Dunn, Biology Dept., Brookhaven National Lab., Long Island, NY, USA) harbouring pARC0558 were grown in LB with 50 μg/ml kanamydn till an O.D. at 600 nm of 0.6 and induced with 0.01 mM isopropyl thiogalactoside (IPTG) for 6 hours. Following 6 hours of induction, cells were harvested and broken by passing through a French press. After centrifugation at low speed to remove unbroken cells and debris, the cytosolic (soluble) fraction was obtained by either of the following two methods: (1) following a procedure described Page et al. (1982) in which the pellet, membrane and soluble proteins are separated by sucrose gradient centrifugation; or (2) by spinning the obtained supernatant at 200,000 x g for 90 minutes, whereafter the supernatant obtained is taken as the cytosolic / soluble protein fraction. 1.3. Penidllin binding of expressed PBP lAdel23 The obtained cytosolic fraction was tested for the presence of mutant PBP 1A by following the method of Rojo et al. (1984). This procedure involves using [ 175 IJcephradine as the labelled penicillin as it is specific for PBP 1A. Mutant PBP lAdel23 capable of binding the labelled cephradine could be demonstrated in the cytosolic fraction. Approximately 50% of the expressed mutant protein fractionated as a soluble protein, while the remaining 50% fractionated into the inclusion body and/or into the membrane assodated fractions. Consequently, enhanced levels of active mutant PBP lAdel23 were obtained since the cells were induced with sub optimal concentration of IPTG and the since cultures were grown at 22°C The penicillin binding profile of the soluble PBP lAdel23 is shown in Fig. 4. 1.4. Purification of soluble PBP lAdel23 The cell pellet of E.coli BL26 (DE3) / pARC0558 obtained following 6 hours of induction at 22°C was washed twice with buffer A (30 mM Tris-Cl, pH 8.0; 10 mM EDTA; 10 μg/ml leupeptin; 10 μg/ml aprotinin; 5 mM DTT) and resuspended in the same buffer. The cell suspension was passed through a French press at 1200 psi. The lysate was spun at 10,000 rpm for 10 minutes and the obtained supernatant centrifuged at 200,000 x g for 45 minutes. The obtained supernatant was then adjusted to 30% saturation with ammonium sulphate. The mixture was centrifuged at 12,000 rpm for 10 min and the pellet resuspended in buffer A containing 1 M NaCl. The dissolved pellet was then treated with Cephradine-Affigel 10 matrix. Cephradine was, conjugated to Affigel 10 following the instructions of the manufacturers (Biorad Laboratories, USA). The soluble PBP lAdel23 containing fraction, dissolved in buffer A containing 1 M NaCl, was incubated 16 hrs at 4°C with cephradine-affigel 10 beads. The beads were then washed with Buffer A containing 1 M NaCl until the absorbance at 280 n was nearly zero. Elution of PBP lAdel23 was monitored by assaying for penicillin binding activity in the wash. This activity was measured using [ IJcephradine prepared as described in Rojo et al. (1984). Bound PBP lAdel23 was eluted from the beads using 1 M hydroxylamine (pH 8.5) at 25°C for 120 minutes. This fraction was concentrated by ultrafiltration using YM 30 filters (Amicon, USA) in Buffer A with 0.25 M NaCl. The ultrafiltration also resulted in the removal of hydroxylamine. The purified fraction containing >85% of the protein species corresponding to PBP lAdel23 showed both penicillin binding and transglycosylase enzyme activities. The protein profile as seen by Coomassie Brilliant Blue staining and the [ 1 _?5IJcephradine / penicillin binding profile of the different fractions, obtained during the various stages of purification, are shown in Fig. 5. The N-terminal amino add sequence of the soluble PBP lAdel23 was confirmed by sequencing the purified protein. 1.5. Transglycosylase activity of soluble PBP lAdel23 The transglycosylase activity of the soluble PBP lAdel23 protein was measured using essentially the method described by Ishino et al. (1980). The substrate for the detection of the enzymic activity were essentially prepared and purified following the protocols described by Heijenoort et al. (1992). The concentration dependent transglycosylase activity of PBP lAdel23 measured as the amount of peptidoglycan formed was compared to the amounts of peptidoglycan formed by different concentrations of the membrane bound form of native PBP 1A. As seen in Fig. 6, the peptidoglycan polymerizing efficiency of the mutant soluble PBP lAdel23 was nearly identical to the enzymic activity of the membrane bound form of the protein. It has consequently been found that the elimination of the 23 amino acid residue stretch does not interfere with the ability of the protein to assume its native structure capable of both the enzymatic activities, i.e. the transglycosylase and the transpeptidase activities. EXAMPLE 2 2.1. Construction of gene encoding soluble form of E.coli PBP IB The ponB gene encoding PBP IB was obtained on a plasmid pBS96 from Prof. B.S. Spratt, Microbial Genetics Group, School of Biological Sciences, University of Sussex, Brighton, UK. The construction of pBS96, as well as the nucleotide sequence of the wild-type ponB gene and the derived amino add sequence, are described in Broome-Smith et al. (1985). The hydropathy plot of the N-terminal approximately 150 amino acids as derived using the method of Kyte and Doolittle (1982) is shown in Fig. 7. Analysis of the hydropathidty plot indicated that the amino adds at positions 65 to 87 of the PBP IB sequence contributed largely to the hydrophobicity of the N-terminus and can be putatively assigned to be the membrane anchoring domain of the protein. In addition, β-lactamase studies of Edelman et al. (1987) had indicated that amino adds C-terminal to amino acid position 87 were present in the periplasmic space of the E.coli cell and that amino adds N-terminal to position 65 of PBP IB were within the cytoplasm of the cell. The strategy employed to construct a mutant ponB gene encoding a soluble form of PBP IB is shown in Fig. 8. Initially a DNA fragment of approximately 200 bp of the 5'-end of the ponB gene was amplified by PCR, from the ponB gene on the plasmid pBS96 (Broome-Smith et al, 1985). The oligonucleotide primers used were 5'-primer TG-77 (5'-GAA AAA CCA TGG CCG GGA ATG ACC-3') which includes a Ncol restriction enzyme site which also coinddes with the start ATG codon of the sequence, and 3' -primer TG-84 (5'-AAG TCG CGA GCC GCG TTT GCC AC-3') which includes a site for the restriction enzyme Nrul and encodes for amino acids corresponding to position 64 of the PBP IB sequence. Step 1: The PCR amplified fragment following restriction with the enzymes Ncol and Nrul was cloned into the Ncol - Nrul sites of the cloning vector pBR 329 (Covarrubias et al., 1982). Ligation, transformation and screening were carried out using standard protocols and the recombinant plasmid with the expected structure labelled pARC0547 (Fig. 8) was obtained. Another DNA fragment of approximately 1.2 kb was amplified by PCR using primer sequences corresponding to amino acid 87 to 480. This DNA fragment encodes the C-terminal half of the TG domain of PBP IB. The primers used were 5'-primer TG-79 (5'-CGG ATA TCG ATC AAA AAA TTC GTA GCC G-3') which induded the nucleotide sequence for the cleavage site for the restriction enzyme EcoRV, and 3'-primer TG-80 (5'-GCG GAT CCT TAG TCG ACG ACC ACA ATC GCA G-3') which included the sequence for BαmHI cleavage. Step 2: The PCR amplification of this fragment was done using the ponB gene on pBS96 (Broome-Smith et al., 1985) DNA as template. The amplified fragment was cloned into the EcoRV - BαmHI sites of pBR 329 (Covarrubias et al., 1982) using standard protocols. The recombinant plasmid obtained was labelled pARC0534 (Fig. 8). Step 3: The 200 bp Ncol - Nrul fragment cloned in pARC0547 was excised as a Ncol - Nrul fragment and cloned into Ncol - EcoRV cleaved pARC0534 to obtain pARC0551 (Fig. 8). The mutant ponB gene on pARC0551 has DNA sequences coding for the N-terminal 64 amino adds of PBP IB fused to the nucleotide sequences encoding the amino acids 88 to 480. A 1.3 kb Pstl - Bamr DNA fragment of pBS96 was then ligated to Pstl - BαmHI deaved pARC0551 and the ligation mixture transformed into E.coli DH5α using standard procedures. Individual transformants were then screened and colonies harbouring recombinant plasmid with the expected structure identified. The plasmid was labelled pARC0552. A Ncol - BαmHI fragment from pARC0552 encompassing the entire mutant ponB gene was then excised and ligated to the T7 expression vector pARC038 to obtain pARC0559 (NCIMB 40667; Fig. 9). The 3'-end of the cloned fragment of Step 1 has the nucleotide sequence TCG (partial Nrul site sequence) while the 5'-end of the fragment cloned in Step 2 has the sequence ATC (partial EcoRV cleavage sequence). The junction nucleotide sequence which is the outcome of the fusion of TCG and ATC results in the introduction of the codons for serine and isoleudne. Thus the mutant ponB gene encodes a PBP IB with the amino add sequence 1 to 64 corresponding to the wild type PBP IB fused to the sequence 87 to 844. The two stretches are joined by the amino adds serine and isoleudne. The nucleotide sequence of the mutant ponB gene is shown as SEQ ID NO: 3 and the derived amino add as SEQ ID NO: 4. 2.2. Expression of soluble PBP IB The plasmid DNA of pARC0559 was transformed into the T7 expression host E.coli BL 26 (DE3) and the restriction map profile of the transformed plasmid confirmed using standard procedures. E.coli BL26 (DE3)/pARC0559 were grown at 22°C and induced with 0.01 mM IPTG and the cells allowed to grow for 6 hours. Cells were then harvested and broken by passage through a french press. The lysate was centrifuged at 10,000 rpm for 10 minutes and the supernatant obtained was centrifuged at 200,000 x g for 45 minutes in a Beckman ultracentrifuge. 2.3. Characterization of the expressed soluble PBP IB The obtained supernatant, i.e. the cytosolic / soluble fraction, was tested for the presence of the mutant PBP IB using [ I] ampidllin as the radio-ligand. The r 25 I]ampicillin was prepared as described by Rojo et al. (1984) for the preparation of [ 125 I]cephradine. The mutant PBP IB was detected in the soluble fraction and bound radioactive ampidllin. Soluble PBP IB could also be purified using Ampidllin - Affigel beads by a procedure analogous to the one described in Section 1.4. The protein profile of the different fractions seen by Coomassie Blue staining and the binding of [ I] ampidllin of the enriched PBP IB fraction is shown in Fig. 10. The purified protein was enzymatically active in the peptidoglycan transglycosylase assay (Heijenoort et al., 1992) and bound penicillin with an affinity comparable to that of the membrane bound native PBP IB. EXAMPLE 3 3.1. Construction of gene encoding soluble form of Streptococcus pneumoniae PBP 1A The molecular architecture of the S.pneumoniae PBP 1A is predicted to be similar to that of E.coli PBP 1A and PBP IB protein in the fact that the protein is anchored to the membrane via a N-terminal membrane anchoring sequence. The nucleotide sequence of the gene encoding native membrane bound S.pneumoniae PBP 1A and its derived amino acid sequence are described in Martin et al., (1992). The hydropathicity profile of the N-terminal 100 amino adds as derived by the Kyte and Doolittle plot is shown in Fig. 11. A stretch of 38 amino adds contributed significantly to the hydrophobia ty of this region and was assumed to be the membrane interacting domain. A mutant gene of S.pneumoniae PBP 1A was constructed by deleting the nucleotide sequence coding for the N-terminal 38 amino adds of S.pneumoniae PBP 1A. Using standard PCR protocols, sequences encoding the wild type S.pneumoniae PBP 1A gene was amplified as a 2.5 kb DNA fragment from the chromosome of S.pneumoniae strain PM1 (obtained from S.A. Lacks, Biology Department, Brookhaven National Laboratory, Upton, New York, USA) (Lacks, 1968) using the primers designed based on the sequence reported by Martin et al. (1992) and the amplified fragment cloned into the pneumococcal vector pLS 101 (Balganesh and Lacks, 1984). The mutant gene encoding a soluble form of S.pneumoniae PBP 1A was constructed by using of plasmid DNA harbouring the wild type gene as template and amplifying a 2.3 kb DNA fragment by using PCR following standard procedures. The sequence of the primers used were 5'-primer TG-24 (5'-TAC GTT ACC ATG GCT CCT AGC CTA TCC-3') and 3'-primer TG-25 (5'-GAC AGG ATC CTG AGA AGA TGT CTT CTC A-3'). The 5'-primer TG-24 includes the sequence for the restriction enzyme Ncol while the 3' -primer TG-25 includes the site for the restriction enzyme BαmHI. The Ncol and BαmHI digested PCR amplified DNA fragment was ligated to Ncol - BαmHI cleaved pARC039. The plasmid pARC039 is a derivative of pET 8c (Studier et al., 1990) in which the gene coding for the β-lactamase has been replaced by a kanamydn resistance cartridge. Following ligation and screening using standard protocols, the structure of the recombinant plasmid was confirmed by detailed restriction mapping 6082 _ 27 _ and transformed into the T7 expression host Exoli BL 21 (DE3) (Studier et al., 1990). The recombinant plasmid was labelled pARC0512 (NCIMB 40665) and is schematically represented in Fig. 12. The nucleotide sequence of the mutant S.pneumoniae PBP 1A gene is shown as SEQ ID NO: 5 and the derived amino add sequence is shown as SEQ ID NO: 6. 3.2. Expression and characterization of soluble form of Streptococcus pneumoniae PBP 1A The gene coding for soluble S.pneumoniae PBP 1A was expressed by a procedure analogous to the one described in Section 1.2.. The cytosolic fraction of E.coli BL 21 (DE3)/pARC0512 was isolated and tested for the presence of the soluble form of the S.pneumoniae PBP lAdel38. The radioactive ligand used for the binding studies was [ HJbenzyl penicillin (Amersham) which was prepared as described earlier. Approximately 50% of the expressed protein from the mutant gene was found to be in the soluble fraction and bound [ 125 I]penicillin (Rojo et al., 1984) or -a [ Hjpenidllin (Amersham) when the culture was grown and induced at 22°C with 0.01 mM IPTG. The growth and induction conditions were critical for the efficient recovery of the soluble protein, as growth at higher temperatures or induction with higher concentrations of IPTG resulted in the majority of the protein becoming inactive and forming inclusion bodies. Optimum levels of soluble active protein was found following induction for 6-8 h. (Fig. 13). The soluble S.pneumoniae PBP lAdel38 protein could also be efficiently purified essentially following the protocol used for the purification of the soluble Exoli PBP IB protein. The effidency of penicillin binding of the soluble PBP lAdel38 was comparable to that of the native membrane bound S.pneumoniae PBP 1A. EXAMPLE 4 4.1. Transglycosylase defident Exoli PBP IB The conserved amino acids within Region 2 (Fig. 14) were chosen for site- directed mutagenesis. Within this stretch of 10 amino adds three different mutations were constructed: (a) the glutamines at position 270 and 271 of the PBP IB sequence were changed to alanines; (b) the glutamines at position 270 and 271 of the PBP IB sequence were changed to leudnes; and (c) a deletion of the nucleotide sequence encoding amino adds from position 264 to 271. Mutants of the ponB gene were constructed essentially following the procedure of Kunkel et al. (1985). A 1.5 kb EcoRI - Sail fragment of the ponB gene of the plasmid pBS96 was exdsed and cloned into EcoRI - Sail cleaved M13mpl9 following standard protocols. (a) The primer used for mutating the nudeotide sequence coding for glutamine residues 270 and 271 into a sequence coding for alanine residues was TG-21: 5'-ACG CTG ACG GCC GCT CTG GTG AAA-3' T L T A A L V K (b) The primer used for mutating the sequence coding for the glutamine residues 270 and 271 into leudne residues was TG-23: 5' -ACG CTG ACG CTA TTG CTG GTG AAA-3' T L T L L L V K (c) The primer used for creating a deletion of the nucleotides encoding amino adds at position 264 to 271, all of which are within the conserved Region 2, was TG-22: 5'-CGC ACG GTA CAG CTG GTG AAA AAC-3 ' R T V Q L V K 260 261 262 263 272 273 274 (amino acid no.) Following mutagenesis, the nucleotide sequence of the mutagenized EcoRI - Sail fragment was determined following the protocol of Sanger et al. (1977). The sequencing confirmed the nucleotide changes and also ruled out any extraneous changes. This mutated 1.5 kb DNA fragment was ligated back to EcoRI - Sail cleaved pBS96 and the ligated DNA transformed in to Exoli DH5α cells following standard protocols. Kanamydn resistant transformants were analyzed for their plasmid profiles and the plasmid with the TG-21 mutation (a) was labelled pARC0438 (NCIMB 40661). The mutant protein is referred to as PBP IB QQ-AA (SEQ ID NO: 7). The plasmid with the mutation (b) introduced by TG-23 was labelled pARC0468 (NCIMB 40662). The mutant protein is referred to as PBP IB QQ-LL (SEQ ID NO: 8) The plasmid with the deletion (c) obtained using TG-22 was labelled pARC0469 (NCIMB 40663). The mutant protein is referred to as PBP lBdelβ (SEQ ID NO: 9). The four plasmid DNAs of pBS96, pARC0438, pARC0468 and pARC0469 were individually transformed into Exoli ponB-.spc? cells (Broome-Smith et al., 1985) in which a deleted ponB gene had been marked with spectinomydn resistance marker. 82 _ 3(> _ PCI7SE95/00761 Exoli ponB spc 1 cells having the individual plasmids pBS96, pARC0438 or pARC0469 were grown and membrane preparations made following the procedure described by Spratt (1977) and the profile of the penicillin binding proteins analyzed on a 8% SDS-PAGE following labelling with radioactive penicillin. The mutant proteins were initially analyzed for in vivo stability and localization into the membrane using anti-PBP IB sera raised against purified membrane bound native PBP IB (Fig. 15). The mutant proteins were found to be localized to the membrane and no degraded protein fragments reacting with the antibody could be detected indicating no gross instability. In addition the mutant proteins bound penidllin with an affinity comparable to that of the wild type PBP IB (Fig. 15). After assaying for transglycosylase activity as described in Heijenoort et al. (1978), no activity could be detected in the membranes expressing the mutant proteins, while the membrane with the wild type PBP IB showed transglycosylase activity. This defines the amino adds 263 to 271 as being critical for transglycosylase activity. The ability of the mutant proteins to bind penicillin with an affinity comparable to that of the wild type suggests that the transpeptidase activity of the mutant proteins would also be comparable to that of the wild type. Knowing that the bifunctional protein PBP IB expressed on a plasmid can in trans complement the deletions of both ponA and ponB (Yousif et al., 1985) the ability of the transglycosylase negative / transpeptidase positive proteins PBP IB QQ-AA and PBP lBdelβ to complement the absence of chromosomally encoded PBP 1A and IB was tested. The wild type ponB and the mutant ponB genes were doned into low copy vector pMAK 705 (Hamilton et al., 1989). The resulting plasmids were designated pARC0462, (wild type ponB, Fig. 16), pARC0463, (poπBdelβ, Fig. 17) and pARC0470 (ponB QQ-AA, Fig. 18). The plasmids were individually transformed into E.coli del ponA (E.coli with a deletion of the ponA gene). E.coli del ponA /pARC0462, Exoli del ponA/pARC0463 and E.coli del po/i A/pARC0470 were used as recipients of the PI phage for the transduction of the ponB-.spc? marker. The transduction was performed as described by Miller (1972) The phage PI lysate was made on E.coli ponB-.spc* strain (Yousif et al., 1985). Following infection, the infected cells were plated on spectinomydn. Integration of the DNA fragment harbouring and ponB.spc transduced into any of the recipients results in the inactivation of the chromosomal ponB gene rendering the chromosome ponA ' and ponB ' . This genotype being lethal for the cell, the E.coli spectinomydn resistant transductants can remain viable only if the plasmid encoded ponB or the ponB mutant can functionally complement in trans. The following E.coli strains were subject to phage PI transduction analysis of trans-complementation: (1) E.coli AMA 1004 which has chromosomally coded wild type ponA and ponB; (2) E.coli AMA 1004 which has a chromosomally inactivated ponB and is the host for the plasmid coded mutant ponB genes; (3) E.coli AMA 1004 host bearing the plasmid pARC0462 encoding the wild type ponB gene; (4) E.coli AMA 1004 host bearing the plasmid pARC0463 encoding PBP lBdelδ; and (5) Exoli AMA 1004 host bearing the plasmid pARC0470 encoding PBP IB QQ-AA. Results (Number of Km r transductants / ml) (1) Exoli AMA 1004 3.0 x 10 4 (2) E.coli AMA 1004, ponB:spc? < 1 (3) Exoli AMA 1004, ponB.sp 1 (PBP IB wt) 1.1 x 10 4 (4) Exoli AMA 1004, ponB:spc r (PBP lBdelβ) < 1 (5) Exoli AMA 1004, ponB.spc 1 (PBP IB QQ-AA) < 1 A comparable number of transductants were obtained for an internal marker : trp transduction using the same PI phage lysate. The above results show that viable transductants could be obtained only with wild type PBP IB, indicating that the TG " TP + product encoded by ponB QQ-AA or ponBde\8 could not complement the loss of chromosomally encoded PBP 1A and IB. However, as these mutant proteins bind penicillin and thus can be assumed to have transpeptidase activity, the inability to complement must be the absence of the transglycosylase enzymic activity. These results confirm the essential nature of the transglycosylase activity of PBP 1 A or IB for the viability of the Exoli cell. The mutants described define the Region 2 to be involved in the transglycosylase activity of the protein. As this stretch of amino adds is conserved within the four high molecular weight penicillin binding proteins namely E.coli PBP 1A, IB and S.pneumoniae 1A and the 94 kDa protein of H.inβuenzae (Fig. 14) it is reasonable to assume similar catalytic or structural involvement of this region in all the transglycosylase enzymes utilizing substrates similar to that used by PBP 1A and IB of E.coli. 4.2. Transglycosylase deficient Exoli PBP 1A The conserved Region 2 was chosen for site-directed mutagenesis and the nucleotide sequence coding for glutamine at positions 123 and 124 of Exoli PBP 1A was changed to a sequence coding for alanine by PCR mutagenesis as follows. The 5' half of the ponA gene was amplified as 2 fragments, the 5'-fragment corresponding to amino add 1 to 123 (fragment A) and the 3'- fragment corresponding to amino acid 124 to 434 (fragment B). The sequence of the 5'-primer used for the amplification of fragment A was TG-93 (5'- GCG CGG ACC ATG GTG AAG TTC GTA AAG TAT-3') while the 3' -primer used for the amplification of fragment A was TG-106 (5'-CAG TGC TGC AGT AAT GGT ACT TGC CCC TTG-3'). The 3'-primer for fragment A amplification included the sequence for the restriction enzyme Pstl which allowed the conversion of the sequence encoding the glutamine residues in position 123 and 124 into a nucleotide sequence coding for alanine residues. Fragment B was amplified with the 5' -primer TG-107 (5'-ATT ACT GCA GCA CTG GCG AGA AAC TTC TTC-3') and the 3'-primer TG-108 (5'-TCG CGA GAT ATC TGG CGG ATT GAT CGA CAC-3'). The 5'-primer for amplifying fragment B included the sequence for the restriction enzyme Pstl overlapping the sequence with that of 3'-primer for amplifying fragment A. Ligation of the 3'-end of fragment A to the 5'-end of fragment B recreated the site for Pstl and resulted in the change of the nucleotide sequence encoding glutamine 123 and 124 into alanine 123 and 124. The amplified fragments A and B were individually cloned into pBR 329, and corresponding clones pARC0565 and pARC0566 were obtained. Fragment A and B obtained from pARC0565 and pARC0566 were ligated to obtain pARC0567. The ponA sequences were completed by introdudng an Xhol - BαmHI fragment of pARC0489 (which is identical to pARC0558 (Fig. 3) except for having additional Lαcl and Lac operator sequences) into pARC0567 to obtain pARC0568. The MM - Bglll fragment of pARC0568 which induded the Q j23 - Q124 t0 ^123 " ^124 mutate d region was then used to replace the otherwise identical M/ I - Bglll fragment of pBS98 to obtain the plasmid pARC0571 (Fig. 19; NCEMB 40668). The mutant protein was labelled PBP 1A QQ-AA (SEQ ID NO: 10). Expression studies on the mutant indicated that the mutant protein was localised to the membrane (as detected by anti PBP 1A antibodies) and bound penicillin with an affinity comparable to that of the native PBP 1A (Fig. 20). An in vivo complementation assay, similar to that described in the previous section, was performed by checking the ability of mutant PBP 1A protein to complement in trans. The in vivo complementation was performed using phage PI transduction and transducing ponB.spc? into the host E.coli (redpient) del ponA harbouring the plasmid encoding the mutant protein PBP 1A QQ-AA. In order to carry out the complementation analysis the wild type ponA gene was cloned into the low copy vector pMAK 705 (Hamilton et al, 1989) to obtain pARC0583 and the mutant ponA gene encoding PBP 1A QQ-AA cloned into pMAK 705 to obtain pARC0582. The following E.coli strains were subject to phage PI transduction analysis of trans-complementation: (1) Exoli AMA 1004 which has chromosomally coded ponA and ponB; (2) Exoli AMA 1004 ponA which has a chromosomally inactivated ponA and is the host for the plasmid coded mutant ponA genes; (3) host bearing the plasmid pARC0583 encoding the wild type ponA gene; (4) host bearing the plasmid pARC0582 encoding PBP 1A QQ-AA. Results (Number of Spc 1 transductants / ml) (1) Exoli AMA 1004 2.1 x 10 3 (2) Exoli AMA 1004, ponA < 1 (3) Exoli AMA 1004, ponA (PBP 1A wt) 1.64 x 10 3 (4) Exoli AMA 1004, ponA (PBP 1A QQ-AA) < 1 A comparable number of transductants were obtained for internal marker : trp transduction using the same PI phage lysate. As shown above, no viable transductants could be obtained with E.coli del ponA / pARC0582 as recipient indicating that the mutant PBP 1A QQ-AA could not complement the absence of chromosomally encoded PBP 1A/1B. This indicates that the Q j23 and Q j2 4 of region 2 of PBP 1A also affects transglycosylase activity of the protein as the loss of the complementing function must be a reflection of the loss of transglycosylase activity. The transpeptidase activity of the protein is unaffected as tested by its affinity to bind penicillin. These results argue in favour of the region 2 as a critical stretch of amino acids involved in the transglycosylase enzymic function and may be the explanation for the strong evolutionary conservation of this stretch of amino adds. EXAMPLE 5 5.1. Truncated E.coli PBP IB A mutant gene encoding the truncated PBP IB consisting of the N-terminal 553 amino acids was constructed by PCR amplification using the 5'-primer TG-77 (5'-GAA AAA CCA TGG CCG GGA ATG ACC-3') and the 3'- primer TG-116 (5'- ATG GGA TCC TTA ATC ATT CTG CGG TGA-3'). The 5' end of the primer corresponded to the amino acid 553 in the wild type followed by the stop codon and a site for the restriction enzyme BαmHI. A fragment of 1.7 kb was amplified using pBS96 DNA as template. The PCR amplified fragment was cut with Psfl and BαmHI and cloned into Pstl-BαmHI restricted pARC0555 (pARC0555 has the full length ponB gene cloned as NcoI-BαmHI fragment into the expression vector pETlld. The Ncol site includes the initiation codon ATG) to obtain pARC0592 (NCIMB 40669; Fig. 21) The expressed protein (SEQ ID NO: 11) was shown to have transglycosylase activity, thus confirming the functional independence of this domain. The soluble truncated PBP IB, i.e. PBP IB with N-terminal 553 amino acids but lacking the membrane anchoring hydrophobic domain from 65-87, was constructed by replacing the Psfl-Bα HI fragment of pARC0559 (Fig. 9) with the Pstl-Bα HI fragment of pARC0592 to obtain pARC0593 (NCIMB 40670; Fig. 22). The mutant ponB gene encodes the soluble form of PBP IB and the expressed protein (SEQ ID NO: 12) was found to have transglycosylase activity. 5.2. Minimum substrate binding domain of truncated E.coli PBP IB Detailed computer analysis of the anatomy of the presumptive TG domain (aa 1-553) of PBP IB indicated that aa 210-368 were probably sufficient for the binding of the lipid linked substrate and the transglycosylase reaction. This stretch of amino acids includes the 3 conserved domains Region I, II and III. The mutant gene encoding the truncated protein stretch 210-368 was constructed as follows. A fragment of approx size 480 bp was amplified from pBS96 as substrate with the 5' -primer having the sequence TG-154 (5'-CAA TCC ATG GGT GAG CAG CGT CTG TTT G-3') were the initiation ATG codon is immediately followed by the sequence encoding the 210th amino add of PBP IB. The 3'-primer corresponded to the sequence TG-155 (5'-T CCA GAA TTC CAG TTT TGG GTT ACG-3') were the sequence encoded the amino add 368 of PBP IB followed by the nudeotide sequence that provides the restriction site for EcoRI, enabling fusion to sequences encoding an enterokinase site and a histidine stretch, which allows rapid purification of the protein on an Ni affinity column (cf. section 6.2 below). A NcoI-EcoRI fragment was cloned into the plasmid pARC0400 that was restricted with NcoI-EcoRI to obtain the recombinant plasmid pARC0392 (NCIMB 40659; Fig. 23). The recombinant plasmid was transformed into Exoli BL26 (DE3) and a protein of approximately 17 kDa was detected largely in the soluble fraction after induction with IPTG. Along similar lines the minimum substrate binding region of PBP 1A could be predicted to involve the stretch 62-220 in the wild type protein. Production of this protein as a fusion with a histidine stretch allows high efficiency affinity purification of the expressed product using the Ni column. That the results will be similar to that obtained with truncated PBP IB can be antidpated. EXAMPLE 6 6.1. N-terminal fusion of soluble E.coli PBP 1A to glutathione-S-transferase Fusion of the po«Adel23 gene at its 5'-end in frame to sequences coding for glutathione-S-transferase was made as described in the following section. The vector chosen for the fusion gene construction was pGEX-3X obtained from Pharmada Biochemicals. In order to fuse the 5'-initiation ATG of 6082 _ 3& _ poπAdel23 in frame with the gene encoding glutathione-S-transferase a BαmHI site was introduced using a PCR primer whose sequence included the sequence for the restriction enzyme EcoRI. The 5' -primer used was TG- 115: 5'-TCG AGG ATC CCC ATG GGC CTA TAC CGC TAC ATC G-3 ' EcoRI BamHI The 3'-primer used was TG-106, described in Section 4.2. The PCR amplified DNA Fragment A was digested with BαmHI and Pstl and cloned into the BαmHI - Pstl sites of the standard cloning vector pUC8 to obtain pARC0496. This Fragment A includes the N-terminal 102 amino adds of the PBP lAdel23 protein. A BαmHI - Mlul (site present within the fragment A) 270 bp fragment obtained from Fragment A, a 2.2 kb Mlul - EcoRI fragment which includes the rest of the portion of the ponA gene obtained from pARC0490 (pARC0490 has the wild type txmA.gene cloned into the Xbαl - BαmHI sites of the low copy vector pWKS29 (Fu Wang et al., 1991) facilitating the 3'-end of the ponA del 23 gene to be exdsed as an EcoRI fragment) and a EcoRI - BαmHI cleaved pGEX-3X were ligated together and transformed into competent E.coli cells. Individual transformants were screened for recombinant plasmid and the plasmid with the expected structure was designated pARC0499 (NCIMB 40664; Fig. 24). The encoded fusion product on pARC0499 has the glutathione-S-transferase sequences at its C-terminus linked to PBP lAdel23 sequences via a Factor Xa cleavage recognition sequence. Following induction with 1 mM IPTG, a fusion protein of expected size was found to be induced. The protein bound penicillin and was active in the transglycosylase assay. Following cell lysis by passing the suspension through a French press, the cell free supernatant fraction was prepared as detailed in Section 1.4. for the purification of PBP lAdel23. The supernatant fraction was passed through a Glutathione Sepharose® matrix (Pharmacia Biochemicals) and the bound GST-PBP lAdell23 was eluted with glutathione. The eluted protein was found to be 80% homogeneous. Free glutathione was removed by dialysis and the GST-PBP lAdel 23 was cleaved with factor Xa. PBP lAdel23 thus purified was found to be active in both penidllin binding and the transglycosylase reactions. 6.2. C-terminal fusion of soluble E.coli PBP 1A to histidine stretch Fusion of the po«Adel23 gene at its 3'-end in frame to sequences encoding a stretch of 6 histidines was made as described below. In the first step the r>onAdel23 gene was amplified using pBS98 DNA as template using the 5'-primer TG-115 (5'-TCG AGG ATC CCC ATG GGC CTA TAC CGC TAC ATC G-3') and the 3'-primer TTG-121 (5'-GTT AGA ATT CGA AC A ATT CCT GTG-3'). The 3'-primer introduced an EcoRI site at the 3' end of the poπAdel23 gene while eliminating the translation stop codon. The PCR amplified modified poπAdel23 gene fragment was digested with Pstl and EcoRI to release a 930 bp 5'-end fragment and ligated to Pstl-EcoRI digested pBR 329 to obtain the recombinant plasmid pARC0467. In the next step, a double stranded synthetic oligonucleotide with sequences encoding the six histidines and the DNA sequence coding for amino adds recognised as the enterokinase cleavage site was synthesised and ligated to the newly created EcoRI site at the 3' -end of the ponAdel23 gene on pARC0467. The synthetic oligonucleotides used were TG-122: 82 _4Q_ EcoRI 5 ' -AA TTC GAC GAC GAC GAC AAG CAC CAC CAC CAC CAC CAC TGA TAA G- 3 ' ENTEROKINASE HISTIDINES and TG 123 (5'-GAT CCT TAT CAG TGG TGG TGG TGG TGG TGC TTG TCG TCG TCG TCG-3'). The plasmid pARC0467 was linearised with EcoRI and the synthetic double stranded oligonucleotide ligated. Following ligation a Pstl - BαmHI (Fragment A) was released from the ligation mixture and cloned into the Pstl - BαmHI sites of pARC0558 (Fig. 3), to obtain pARC0400 (NCIMB 40660; Fig. 25). The mutant poπAdel23 fusion gene thus encoded a protein with the PBP lAdel23 sequence fused to the amino acid sequence Asp- Asp-Asp-Asp-Lys fused to His-His-His-His-His-His at its C-terminus. The Asp-Asp-Asp-Asp-Lys sequence is recognised by the protease enterokinase and cleaves following the lysine residue. The six histidine residues confer on the protein the ability to bind to the metal nickel. The recombinant plasmid pARC0400 was transformed in E.coli BL26(DE3) cells and induced under culture and temperature conditions identical to those used for the purification of PBP lAdel23. The cells were lysed by passing through a French press. The lysate was centrifuged at 10,000 rpm for 10 min. The supernatant obtained after low speed centrifugation was then spun at 200,000 x g for 45 min and the supernatant obtained represented the cytosolic fraction. This fraction contained the protein encoded by the fusion gene and the recombinant fusion protein was labelled PBP lAdel23EH. This protein PBP lAdel23EH bound [ ^IJcephradine and was also active in transglycosylase assay. The soluble fraction was passed through a Ni affinity column and bound protein eluted in batches with increasing concentrations of imidazole essentially following the procedure described in 'The Qia Expressionist" obtained from QIAGEN Inc. 9259 Eton Avenue, Chateworth, CA 91311 USA. The majority of PBP lAdel23EH eluted with 250 mM imidazole and was approximately 85% homogenous. It was the only cephradine binding protein eluted from the column. Thus the ability of fusion protein to bind to the Ni column can be easily exploited both for efficient purification and immobilisation of the active protein. EXAMPLE 7 7.1. Use of cell extracts for enzyme assays and in screening The crude cell extract made according to Example 6 can be analyzed for the ability to bind penidllin by reacting with [ Hjampidllin prepared according to Hackenbeck (1983). To adapt the procedure to large-scale screening, a 96 well microtitre plate is used to contain the reactions and the assay is performed using a Beckman Biomek robot. Crude cell extract is mixed with [ 3 HJampidllin for 15 min at 37°C. The proteins in the reactionare are precipitated with TCA and collected on a glass filter, unbound ampidllin is washed off and filters counted in a sdntillation counter. Alternatively, autoradiography can be used to assay the degree of binding of ampidllin. Based on the above method, a competitive assay can be used to assess the ability of test compounds to bind to the transpeptidase site of a PBP variant. In this assay, the test compound is exposed to the crude cell extract for 15 min prior to the addition of ampidllin. A positive result is indicated by a reduction in the amount of radioactivity present on the glass filter. 7.2. Use of soluble immobilised protein in screening Protein containing a histidine peptide which has been purified as described can be used for screening for compounds which inhibit transpeptidase activity or transglycosylase activity. The purified full length or truncated protein is immobilised onto agarose gel to which Ni(II) has been coupled. Aliquots of the beads containing immobilised protein are then transferred to the wells of a microtitre plate, test compounds are added to the plate and incubated before unbound test substance is washed free. Compounds which bind to the transpeptidase site of the bifunctional protein can be detected by adding [ HJampidllin to the reaction vessel and continuing essentially as described above. Alternatively monoclonal antibodies known to bind to the transpeptidase region can be used. Compounds which bind to the transglycosylase site can be assessed in a competitive assay by the use of monoclonal antibodies which bind to the transglycosylase region of the protein. EXAMPLE 8 8.1. Production of monoclonal antibodies to PBP 1A The protocol for the production of monoclonal antibodies (mAbs) was essentially that described in "Antibodies - a laboratory manual" (ed. Harlow David Lane, Cold Spring Harbor, USA). Purified membrane bound PBP 1A was used as the immunogen. Balb-C mice, 6-8 weeks old were immunised with 50 μg of purified native PBP 1A in Freunds Complete Adjuvant. A booster injection of 20 μg PBP 1A in incomplete Freunds adjuvant was given intraperitonially. Two weeks later the presence of serum antibodies was checked by ELISA using PBP 1A as the coated antigen. Mice with circulating antibodies were immunised intraperitonially daily for 4 days with 20 μg of PBP 1A in saline and the mice sacrificed for isolating splenocytes for generating fusions. The myeloma cell line used in fusion experiments was Sp 2/0-Ag 14 and these cells were fused with splenocytes from immunised mice at an ratio of 10 : 1. Fusion was carried out using standard protocols and antibody production from the clones was monitored by ELISA against PBP 1A when the cells were > 90% confluent. 72 high producing clones were expanded to 24 well plates and the secreted antibody characterised using the following screens: (1) ELISA against membrane bound form of PBP 1A; (2) ELISA against soluble form of PBP lAdel 23; (3) Dot blot analysis against membrane bound PBP 1A to eliminate monoclonals reacting with the detergent solubilised purified PBP 1A protein only due to changes in the configuration during purification; and (4) ELISA against membrane bound form of PBP IB. Based on these screens, a panel of 5 secreting clones were selected and subcloned twice to ensure monoclonality. Asdtes with these hybridoma clones were raised following standard procedures and IgG was purified from these asdtes fluids, using Protein G-Sepharose affinity chroma tography as recommended by the manufacturers of Protein G-Sepharose (Pharmacia Biochemicals). These purified antibodies react spedfically with PBP 1A in both the membrane bound and the soluble forms in ELISA, Dot blots and in Western blotting. Clones were obtained by a cloning procedure employing 3 cells / well. To ensure the monoclonality these clones were subcloned into 96 well microtitre plates by hmiting dilution at 1 cell / well. The wells receiving one cell were carefully confirmed under the microscope and allowed to grow with macrophage feeder layers so as to obtain progeny from a single hybrid cell. Following sub-cloning the secretion of mAbs to PBP 1A was again assayed in ELISA using full length PBP 1A. Finally two clones from each parent hybridoma were selected and one of them was expanded as asdtes in pristine primed Balb/c mice. All the five clones adapted to grow in peritoneal cavities and produced ascitic mAbs. The asdtic mAbs were titrated against purified PBP 1A in ELISA. All the ascitic mAbs had a titre of > 5 x 10^ in ELISA and recognised full length protein in western immunoblots. The asdtic mAbs were purified by protein-G affinity columns. The immunoglobulin isotype of mAbs was determined by mouse lg - isotype by ELISA using a kit obtained from Sigma chemicals USA. Four of the monoclonals belonged to IgGl and one belonged to IgG2a immunoglobulin isotype. Further characterization of mAbs was done by using full length membrane bound PBP 1A/1B in western blots. In addition the transglycosylase (TG) and transpeptidase (TP) domain specifidty of mAbs was determined by using various truncated forms of the membrane-bound N-terminal of PBP 1A, N-terminal of PBP IB and C-terminal of PBP IB in Western immunoblots. Various full length and truncated membrane bound PBPs were expressed and the prepared membrane fractions were resolved on a SDS-PAGE. The proteins were transferred onto nitrocellulose membranes and subjected to western blot analysis using polydonal E.coli PBP 1A antibodies and monoclonal antibodies. Assessment of the penicillin binding inhibitory potential of the mAbs was determined essentially following the protocol described by den Blaauwen et al. (1990). The protein-G affinity purified mAbs was preincubated with PBP 1A followed by addition of [^ijbenzyl penidllin or [ ^IJcephradine. Two of the mAbs competitively inhibited binding of the radiolabelled penicillin to PBP 1A. Monodonal antibodies spedfic for the TG domain of PBP 1A have been obtained by screening the secreted antibody of the original hybridoma clones to react with the protein representing the N-terminal 434 amino adds of PBP 1A in western blots. Antibody from clone TG-2 reacted with 082 _4^. P the N-terminal truncated 434 amino acid analogue of PBP 1A but also inhibited (>80% inhibition) the transglycosylase activity of PBP 1A. This indicates that the antibody recognises sequences in the protein which are involved in (a) binding of the substrate; (b) catalysing the enzymic action; or (c) altering conformation of the protein allosterically. In either of the three possibilities, identification of compounds competing for the binding of TG-2 to PBP 1A would represent molecules interacting with identical sequences on PBP 1A. Thus the competitive binding assay could be used as a screening assay for the identification of the TG inhibitory compound. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Hydropathicity profile of E.coli PBP 1A. The figure shows in expanded form the hydropathicity pattern of the N-terminal 55 amino adds of PBP 1A. Figure 2 Schematic representation of the T7 translation fusion expression vector pARC038. vector sequences • gene conferring kanamydn resistance Km r , gene encoding the lactose repressor (lac I ), origin of replication (ori), T7 lac operator promoter, T7 phage terminator. The direction of transcription of the different genes are shown by arrows. Relevant restriction enzyme sites are shown. Numbers next to the restriction site represent the nucleotide position taking the nucleotide at the upper twelve o'clock-position as zero. Figure 3 Schematic representation of the vector pARC0558 encoding soluble PBP lAdel 23 of Exoli. vector sequences = mutant gene encoding PBP lAdel23, kanamydn resistance Km r , lactose repressor (lac Iq) and the origin of replication ori. Figure 4 Expression of soluble PBP lAdel23. Panel A represents the autoradiogram of the [ IJcephradine binding profile of the uninduced and induced cultures of E.coli BL 26 (DE3) harbouring pARC0558. Panel B represents the Coomassie Brilliant Blue staining protein profile of the same uninduced and induced cells. Lane (1): uninduced cytosol fraction; (2): uninduced membrane fraction; (3): induced cytosol fraction; (4): induced membrane fraction; (M): molecular weight markers. Figure 5 SDS-PAGE pattern of purified PBP 1 Adel23. Panel A: Coomassie blue staining. Panel B: [ I] cephradine binding protein profile. Lanes (1): E.coli BL 26(DE3)/pARC0558 cytosolic fraction (200,000g supernatant); (2): 30% Ammonium sulphate supernatant fraction; (3): 30% Ammonium sulphate pellet fraction; (4): Cephradine affigel breakthrough fraction; (5): Molecular weight markers; (6-8): Cephradine affigel eluate. Figure 6 Transglycosylase activity profile of wild type PBP 1A and mutant PBP lAdel23 using purified proteins. (A— A) represents activity of soluble PBP lAdel23; (•— •) represents activity of membrane bound PBP 1A solubilised with octyl-β-glucoside. X-axis represents the concentration of the proteins used in μg. Y-axis represents the quantities of peptidoglycan formed. Figure 7 Hydropathicity profile of Exoli PBP IB. The figure represents the expanded hydropathicity profile of the N-terminal 150 amino acids of Exoli PBP IB. Figure 8 Schematic representation of the cloning of the soluble transglycosylase domain of Exoli PBP IB. vector sequences == sequences encoding ponB gene fragments and β-lactamase The Ncol-Nrul fragment encoding the N-terminal 64 amino adds of PBP IB was doned into the Ncol-EcoRV sites of pARC0534 to obtain the plasmid pARC0551. This recombinant plasmid harbours the gene encoding amino acid 1 to 480 of PBP IB with internal deletion of amino acid 65 to 87. Figure 9 Schematic representation of pARC0559 encoding soluble PBP IB. vector sequences - sequences of the mutant ponB gene encoding the soluble form of PBP IB (solPBP IB), lactose repressor (lac I α ), kanamydn resistance (Km r ) and the origin of replication (ori). Arrows represent direction of transcription of the genes. Figure 10 Purification of soluble PBP IB. Panel A: SDS-PAGE, Coomassie blue staining of the different fractions. Panel B: [ ^] ampidllin binding profile of the same fractions. Lanes (1) and (2): Cytosolic fraction of E.coli BL 26(DE3)/pARC0559 induced cells; (3): Breakthrough fraction of Ampicillin- Affigel column; (4): Molecular weight markers; (5) and (6): Eluted fraction from the Ampidllin- Affigel column. Figure 11 Hydropathicity profile of S.pneumoniae PBP 1A. The figure shows the expanded profile of the hydropathicity profile of the N-terminal 100 amino adds of S.pneumoniae PBP 1A. Figure 12 Schematic representation of the plasmid pARC0512 encoding soluble form of S.pneumoniae PBP 1A. represents vector sequences === represents sequences of the gene encoding soluble PBP 1A of S.pneumoniae (sPBP 1A), kanamydn resistance Km r and the origin of replication (ori). Figure 13 Penicillin binding profile of soluble S.pneumoniae PBP 1A. Host: Exoli BL 21(DE3)/pARC0512. Panel A: Coomassie Blue staining. Panel B: In vivo labelling with [ HJbenzyl penidllin followed by SDS-PAGE. Lanes (1) and (2): Cytosolic fraction of cells induced at 22°C for 2 h and 20 h respectively; (3): Cytosolic fraction of cells induced at 30°C for 2 h; (4): Cytosolic fraction of cells induced at 37°C for 2h; (5): Molecular weight markers. Figure 14 Amino acid alignment of conserved regions of the transglycosylase domain of high molecular weight penicillin binding proteins. The figure compares the conserved residues of the Regions 1, 2 and 3 among E.1A (E.coli PBP 1A), E.1B (Exoli PBP IB), S.1A (S.pneumoniae PBP 1A), and H.inf (Haemophilus inβuenzae PBP 1A). (*) indicates identical amino add residues. Figure 15 Analysis of membrane protein of Exoli cells harbouring plasmids with genes encoding mutant PBP IB. Panel A: rHJbenzyl penidllin binding profile. Panel B: Western blotting with anti-PBP IB sera. Lanes (1): Molecular weight markers; (2): Membrane fraction of Exoli JM 101/pBS96 cells; (3): Membrane fraction of Exoli 900521 ponBSpc 1 cells (This host lacks chromosomal encoded PBP IB); (4): Membrane fraction of E.coli 900521 poπB:spc./pARC0438 cells; (5): Membrane fraction of Exoli 900521 po«B:spc/pARC0469; (6): Membrane fraction of E.coli 900521 poπB:spc/pARC0468. Figure 16 Schematic representation of plasmid pARC0462 encoding wild type PBP IB: vector sequences = sequences of the ponB gene, replication origin (ori), chloramphenicol acetyl transferase (cm r ) and portions of the lac Z multiple cloning site. Figure 17 Schematic representation of plasmid pARC0463 encoding mutant ponB gene. vector sequences = sequences of mutant the ponB gene encoding PBP lBdelβ amino acids, replication origin (ori), chloramphenicol acetyl transferase (cm r ) and portions of the lac Z multiple cloning site. Figure 18 Schematic representation of plasmid pARC0470 encoding mutant ponB gene. vector sequences -== sequences of mutant the ponB gene encoding PBP IB Q 7i_ 2 7 - •^271-272' re pti aαon origin (ori), chloramphenicol acetyl transferase (cm r ) and portions of the lac Z multiple cloning site. Figure 19 Schematic representation of pARC0571 harbouring mutant ponA gene. vector sequences = sequences of mutant ponA gene (PBP 1A QQ-AA), kanamydn resistance Km r origin of replication (ori). Figure 20 [ ^IJPenicillin binding protein profile of wild type and mutant Exoli PBP 1A. Lane (1): Exoli AMA 1004 ponB.spcVpBS 98 (w.t. ponA); (2): E.coli BL21 (DE3) po«B:spc r /pARC0570 (w.t. ponA); (3): Exoli AMA 1004 del poπA/pARC0571 (QQ-AA ponA); (4): E.coli AMA 1004 del ponA/pBS 98 (w.t. ponA); (5): Molecular weight markers. Figure 21 Schematic representation of plasmid pARC0592. vector sequences = sequences of truncated ponB gene encoding for the N-terminal 553 amino adds of PBP IB (hinge IB), kanamydn resistance (Km r ) and origin of replication (ori) Figure 22 Schematic representation of plasmid pARC0593. vector sequences == sequences of mutant truncated ponB gene encoding a soluble form of the truncated N-terminal 553 amino acids of PBP IB (soluble hinge IB), kanamydn resistance Km r and origin of replication (ori). Figure 23 Schematic representation of plasmid pARC0392. vector sequences = sequences of mutant gene encoding truncated fragment of PBP IB protein, representing amino acids 210-368 sequences fused in frame at its 3'-end to sequences encoding a enterokinase site followed by a stretch of 6 histidines, kanamydn resistance Km r and origin of replication (ori). Figure 24 Schematic representation of plasmid pARC0499. vector sequences = sequences of mutant poπ Adel23 gene fused at its 5'-end in frame to sequences encoding Glutathione-S-transferase encoding sequences, β-lactamase amp r and origin of replication (ori). Figure 25 Schematic representation of plasmid pARC0400. vector sequences -= sequences of mutant ponAde\23 sequences fused in frame at its 3'- end to sequences encoding a enterokinase site followed by a stretch of 6 histidines, kanamydn resistance Km r and origin of repUcation (ori). REFERENCES Balganesh, T.S. and Lacks, S. (1984): Gene 29, 221-230 den Blaauwen, T. et al. (1990): J. Bact. 172, 63-70 Broome-Smith, J.K. et al. (1985): Eur. J. Biochem. 147, 437-446 Covarrubias, L. & Bolivar, F. (1982): Gene 17, 79-89 Edelman, A. et al. (1987): Molecular Microbiology 1, 101-106 Fu Wang, R. and Kushner, S.R. (1991): Gene 100, 195-199 Hackenbeck et al. (eds.) The target of penicillin. W. de Gruyter publications, Berlin /New York 1983. Hamilton, CA. et al. (1989): J. Bacteriol. 171, 4617-4622 Heijenoort, Y. van, et al. (1978): FEBS Letters 89, 141-144 Heijenoort, Y. van, et al. (1992): J. Bacteriol. 174, 3549-3557 Ishino, F. et al. (1980): Biochem. Biophys. Res. Comm. 97, 287- 293 Kunkel, T.A. (1985): Proc. Natl. Acad. Sci. U.S.A. 82, 488-492 Kyte and Doolittle (1982): J. Mol. Biol. 157, 105-132 Lacks, S.A. (1968): Genetics 60, 685-706 Martin, C. et al. (1992): J. Bacteriol. 174, 4517-4523 Miller, J.H. (ed.) (1972): Experiments in Molecular Genetics. Cold Spring Harbor Publications. Nakagawa, J.S. et al. (1984): J. Biol. Chem. 259, 13937-13946 Page, W.J. et al. (1982): J. Bacteriol. 151, 237-242 Rojo et.al. (1984): J. Antibiotics. 37, 389-393 Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989): Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY Sanger, et al. (1977): Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467 Spratt, B.S. (1977): Eur. J. Biochem. 72, 341-352 Studier, F.W. et al. (1990): Methods in Enzymology 185, 61-89 Tomb, F. et al. (1991): Gene 104, 1-10 Yousif, S.Y. et al. (1985): J. Gen. Microbiol. 131, 2839-2845 SEQUENCE LI STING ( 1 ) GENERAL INFORMATION : (i) APPLICANT: (A) NAME: ASTRA AKTIEBOLAG (B) STREET: Kvarnbergagatan 16 (C) CITY: Sodertalje (E) COUNTRY: Sweden (F) POSTAL CODE (ZIP) : S-151 85 (G) TELEPHONE: +46-8 553 260 00 (H) TELEFAX: +46-8 553 288 20 (I) TELEX: 19237 astra s (ii) TITLE OF INVENTION: Novel Polypeptides (iii) NUMBER OF SEQUENCES: 13 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO) (2 INFORMATION FOR SEQ ID NO: 1: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2487 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (B» STRAIN: DH5 alpha !vιι) IMMEDIATE SOURCE: (A) LIBRARY: PCR cloning (B) CLONE: pARC 0558 Soluble PBP 1A del 23 (lx) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2487 (IX) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 1..2484 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATG GGC CTA TAC CGC TAC ATC GAG CCA CAA CTG CCG GAT GTG GCG ACA 48 Met Gly Leu Tvr Arg Tyr lie Glu Pro Gin Leu Pro Asp Val Ala Thr 1 5 10 15 TTA AAA GAT GTT CGC CTG CAA ATT CCG ATG CAG ATT TAC AGC GCC GAT 96 Leu Lys Asp Val Arg Leu Gin lie Pro Met Gin lie Tyr Ser Ala Asp 20 25 30 GGC GAG CTG ATT GCT CAA TAC GGT GAG AAA CGT CGT ATT CCG GTT ACG 144 Gly Glu Leu He Ala Gin Tyr Gly Glu Lys Arg Arg He Pro Val Thr 35 40 45 TTG GAT CAA ATC CCA CCG GAG ATG GTG AAA GCC TTT ATC GCG ACA GAA 192 Leu Asp Gin He Pro Pro Glu Met Val Lys Ala Phe He Ala Thr Glu 50 55 60 GAC AGC CGC TTC TAC GAG CAT CAC GGC GTT GAC CCG GTG GGG ATC TTC 240 Asp Ser Arg Phe Tyr Glu His His Gly Val Asp Pro Val Gly He Phe 65 70 75 80 CGT GCA GCA AGC GTG GCG CTG TTC TCC GGT CAC GCG TCA CAA GGG GCA 288 Arg Ala Ala Ser Val Ala Leu Phe Ser Gly His Ala Ser Gin Gly Ala 85 90 95 AGT ACC ATT ACC CAG CAG CTG GCG AGA AAC TTC TTC CTC AGT CCA GAA 336 Ser Thr He Thr Gin Gin Leu Ala Arg Asn Phe Phe Leu Ser Pro Glu 100 105 110 CGC ACG CTG ATG CGT AAG ATT AAG GAA GTC TTC CTC GCG ATT CGC ATT 384 Arg Thr Leu Met Arg Lys He Lys Glu Val Phe Leu Ala He Arg He 115 120 125 GAA CAG CTG CTG ACG AAA GAC GAG ATC CTC GAG CTT TAT CTG AAC AAG 432 Glu Gin Leu Leu Thr Lys Asp Glu He Leu Glu Leu Tyr Leu Asn Lys 130 135 140 ATT TAC CTT GGT TAC CGC GCC TAT GGT GTC GGT GCT GCG GCA CAA GTC 480 He Tyr Leu Gly Tyr Arg Ala Tvr Gly Val Glv Ala Ala Ala Gin Val 145 150 155 160 TAT TTC GGA AAA ACG GTC GAC CAA CTG ACG CTG AAC GAA ATG GCG GTG 528 Tyr Phe Gly Lys Thr Val Asp Gin Leu Thr Leu Asn Glu Met Ala Val 165 170 175 ATA GCC GGG CTG CCG AAA GCG CCT TCC ACC TTC AAC CCG CTC TAC TCG 576 He Ala Gly Leu Pro Lys Ala Pro Ser Thr Phe Asn Pro Leu Tyr Ser 180 185 190 ATG GAT CGT GCC GTC GCG CGG CGT AAC GTC GTG CTG TCG CGG ATG CTG 624 Met Asp Arg Ala Val Ala Arg Arg Asn Val Val Leu Ser Arg Met Leu 195 200 205 GAT GAA GGG TAT ATC ACC CAA CAA CAG TTC GAT CAG ACA CGC ACT GAG 672 Asp Glu Gly Tyr He Thr Gin Gin Gin Phe Asp Gin Thr Arg Thr Glu 210 215 22J GCG ATT AAC GCT AAC TAT CAC GCG CCG GAG ATT GCT TTC TCT GCG CCG 720 Ala He Asn Ala Asn Tyr His Ala Pro Glu He Ala Phe Ser Ala Pro 225 230 235 240 TAC CTG AGC GAA ATG GTG CGC CAG GAG ATG TAT AAC CGT TAT GGC GAA 768 Tyr Leu Ser Glu Met Val Arg Gin Glu Met Tyr Asn Arg Tvr Gly Glu 245 250 " 255 AGT GCC TAT GAA GAC GGT TAT CGC ATT TAC ACC ACC ATC ACC CGC AAA 816 Ser Ala Tyr Glu Asp Gly Tyr Arg He Tyr Thr Thr He Thr Arg Lys 260 265 270 GTG CAG CAG GCC GCG CAG CAG GCG GTA CGT AAT AAC GTG CTG GAC TAC 864 Val Gin Gin Ala Ala Gin Gin Ala Val Arg Asn Asn Val Leu Asp Tyr 275 280 285 GAC ATG CGC CAC GGC TAT CGC GGC CCG GCA AAT GTG CTG TGG AAA GTG 912 Asp Met Arg His Gly Tyr Arg Gly Pro Ala Asn Val Leu Trp Lys Val 290 295 300 GGC GAG TCG GCG TGG GAT AAC AAC AAG ATT ACC GAT ACG CTG AAG GCG 960 Gly Glu Ser Ala Trp Asp Asn Asn Lys He Thr Asp Thr Leu Lys Ala 305 310 315 320 CTG CCA ACC TAT GGT CCG CTG CTG CCT GCC GCA GTC ACC AGC GCC AAT 1008 Leu Pro Thr Tyr Gly Pro Leu Leu Pro Ala Ala Val Thr Ser Ala Asn 325 330 335 CCT CAG CAA GCG ACG GCG ATG CTG GCG GAC GGG TCG ACC GTC GCA TTG 1056 Pro Gin Gin Ala Thr Ala Met Leu Ala Asp Gly Ser Thr Val Ala Leu 340 345 350 AGT ATG GAA GGC GTT CGC TGG GCG CGT CCT TAC CGT TCG GAT ACT CAG 1104 Ser Met Glu Gly Val Arg Trp Ala Arg Pro Tyr Arg Ser Asp Thr Gin 355 360 365 CAA GGA CCG ACG CCG CGT AAA GTG ACC GAT GTT CTG CAA ACG GGT CAG 1152 Gin Gly Pro Thr Pro Arg Lys Val Thr Asp Val Leu Gin Thr Gly Gin 370 375 380 CAA ATC TGG GTT CGT CAG GTT GGC GAT GCA TGG TGG CTG GCA CAA GTG 1200 Gin He Trp Val Arg Gin Val Glv Asp Ala Trp Trp Leu Ala Gin Val 385 390 395 400 CCG GAA GTG AAC TCG GCG CTG GTG TCG ATC AAT CCG CAA AAC GGT GCC 1248 Pro Glu Val Asn Ser Ala Leu Val Ser He Asn Pro Gin Asn Gly Ala 405 410 415 GTT ATG GCG CTG GTC GGT GGC TTT GAT TTC AAT CAG AGC AAG TTT AAC 1296 Val Met Ala Leu Val Gly Gly Phe Asp Phe Asn Gin Ser Lys Phe Asn 420 425 430 CGC GCC ACC CAG GCA CTG CGT CAG GTG GGT TCC AAC ATC AAA CCG TTC 1344 Arg Ala Thr Gin Ala Leu Arg Gin Val Gly Ser Asn He Lys Pro Phe 435 440 445 CTC TAC ACC GCG GCG ATG GAT AAA GGT CTG ACG CTG GCA AGT ATG TTG 1392 Leu Tyr Thr Ala Ala Met Asp Lys Gly Leu Thr Leu Ala Ser Met Leu 450 455 460 AAC GAT GTG CCA ATT TCT CGC TGG GAT GCA AGT GCC GGT TCT GAC TGG 1440 Asn Asp Val Pro He Ser Arg Trp Asp Ala Ser Ala Gly Ser Asp Trp 465 470 475 480 CAG CCG AAG AAC TCA CCA CCG CAG TAT GCT GGT CCA ATT CGC TTA CGT 1488 Gin Pro Lys Asn Ser Pro Pro Gin Tyr Ala Gly Pro He Arg Leu Arg 485 490 495 CAG GGG CTG GGT CAG TCG AAA AAC GTG GTG ATG GTA CGC GCA ATG CGG 1536 Gin Gly Leu Gly Gin Ser Lys Asn Val Val Met Val Arg Ala Met Arg 500 505 510 GCG ATG GGC GTC GAC TAC GCT GCA GAA TAT CTG CAA CGC TTC GGC TTC 1584 Ala Met Gly Val Asp Tyr Ala Ala Glu Tyr Leu Gin Arg Phe Gly Phe 515 520 525 CCG GCA CAA AAC ATT GTC CAC ACC GAA TCG CTG GCG CTG GGT TCA GCG 1632 Pro Ala Gin Asn He Val His Thr Glu Ser Leu Ala Leu Gly Ser Ala 530 535 540 TCC TTC ACC CCA ATG CAG GTG GCG CGC GGC TAC GCG GTC ATG GCG AAC 1680 Ser Phe Thr Pro Met Gin Val Ala Arg Gly Tyr Ala Val Met Ala Asn 545 550 555 560 GGC GGC TTC CTG GTG GAC CCG TGG TTT ATC AGC AAA ATT GAA AAC GAT 1728 Gly Gly Phe Leu Val Asp Pro Trp Phe He Ser Lys He Glu Asn Asp 565 570 575 CAG GGC GGC GTG ATT TTC GAA GCG AAA CCG AAA GTA GCC TGC CCG GAA 1776 Gin Gly Gly Val He Phe Glu Ala Lys Pro Lys Val Ala Cys Pro Glu 580 585 590 TGC GAT ATT CCG GTG ATT TAC GGT GAT ACG CAG AAA TCG AAC GTG CTG 1824 Cys Asp He Pro Val He Tyr Gly Asp Thr Gin Lys Ser Asn Val Leu 595 600 605 GAA AAT AAC GAT GTT GAA GAT GTC GCT ATC TCC CGC GAG CAG CAG AAT 1872 Glu Asn Asn Asp Val Glu Asp Val Ala He Ser Arg Glu Gin Gin Asn 610 615 620 GTT TCT GTA CCA ATG CCG CAG CTG GAG CAG GCA AAT CAG GCG TTA GTG 1920 Val Ser Val Pro Met Pro Gin Leu Glu Gin Ala Asn Gin Ala Leu Val 625 630 635 640 GCG AAG ACT GGC GCG CAG GAG TAC GCA CCG CAC GTC ATC AAC ACT CCG 1968 Ala Lys Thr Gly Ala Gin Glu Tyr Ala Pro His Val He Asn Thr Pro 645 650 655 CTG GCA TTC CTG ATT AAG AGT GCT TTG AAC ACC AAT ATC TTT GGT GAG 2016 Leu Ala Phe Leu He Lys Ser Ala Leu Asn Thr Asn He Phe Gly Glu 660 665 670 CCA GGC TGG CAG GGT ACT GGC TGG CGT GCA GGT CGT GAT TTG CAG CGT 2064 Pro Gly Trp Gin Gly Thr Gly Trp Arg Ala Gly Arg Asp Leu Gin Arg 675 680 685 CGC GAT ATC GGC GGG AAA ACC GGG ACC ACT AAC AGT TCG AAA GAT GCG 2112 Arg Asp He Gly Gly Lys Thr Gly Thr Thr Asn Ser Ser Lys ASD Ala 690 695 700 TGG TTC TCG GGT TAC GGT CCG GGC GTT GTG ACC TCG GTC TGG ATT GGC 2160 Trp Phe Ser Gly Tyr Gly Pro Gly Val Val Thr Ser Val Trp He Gly 705 710 715 720 TTT GAT GAT CAC CGT CGT AAT CTC GGT CAT ACA ACG GCT TCC GGA GCG 2208 Phe Asp Asp His Arg Arg Asn Leu Gly His Thr Thr Ala Ser Gly Ala 725 730 735 ATT AAA GAT CAG ATC TCA GGT TAC GAA GGC GGT GCC AAG AGT GCC CAG 2256 He Lys Asp Gin He Ser Gly Tyr Glu Gly Gly Ala Lys Ser Ala Gin 740 745 750 CCT GCA TGG GAC GCT TAT ATG AAA GCC GTT CTT GAA GGT GTG CCG GAG 2304 Pro Ala Trp Asp Ala Tyr Met Lys Ala Val Leu Glu Glv Val Pro Glu 755 760 765 CAG CCG CTG ACG CCG CCA CCG GGT ATT GTG ACG GTG AAT ATC GAT CGC 2352 Gin Pro Leu Thr Pro Pro Pro Gly He Val Thr Val Asn He Asp Arg 770 775 780 AGC ACC GGG CAG TTA GCT AAT GGT GGC AAC AGC CGC GAA GAG TAT TTC 2400 Ser Thr Gly Gin Leu Ala Asn Gly Gly Asn Ser Arg Glu Glu Tvr Phe 785 790 795 800 ATC GAA GGT ACG CAG CCG ACA CAA CAG GCA GTG CAC GAG GTG GGA ACG 2448 He Glu Gly Thr Gin Pro Thr Gin Gin Ala Val His Glu Val Gly Thr 805 810 815 ACC ATT ATC GAT AAT GGC GAG GCA CAG GAA TTG TTG TG 2487 Thr He He Asp Asn Gly Glu Ala Gin Glu Leu Leu 820 825 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 828 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Gly Leu Tyr Arg Tyr He Glu Pro Gin Leu Pro Asp Val Ala Thr 1 5 10 15 Leu Lys Asp Val Arg Leu Gin He Pro Met Gin He Tyr Ser Ala Asp 20 25 30 Gly Glu Leu He Ala Gin Tyr Gly Glu Lys Arg Arg He Pro Val Thr 35 40 45 Leu Asp Gin He Pro Pro Glu Met Val Lys Ala Phe He Ala Thr Glu 50 55 60 Asp Ser Arg Phe Tyr Glu His His Gly Val Asp Pro Val Gly He Phe 65 70 75 80 Arg Ala Ala Ser Val Ala Leu Phe Ser Gly His Ala Ser Gin Gly Ala 85 90 95 Ser Thr He Thr Gin Gin Leu Ala Arg Asn Phe Phe Leu Ser Pro Glu 100 105 110 Arα Thr Leu Met Arg Lvs He Lvs Glu Val Phe Leu Ala He Arg He 115 120 125 Glu Gin Leu Leu Thr Lys Asp Glu He Leu Glu Leu Tyr Leu Asn Lys 130 135 140 He Tyr Leu Gly Tyr Arg Ala Tvr Gly Val Gly Ala Ala Ala Gin Val 145 150 155 160 Tyr Phe Gly Lvs Thr Val Asp Gin Leu Thr Leu Asn Glu Met Ala Val 165 170 175 He Ala Gly Leu Pro Lvs Ala Pro Ser Thr Phe Asn Pro Leu Tyr Ser 180 185 190 Met Asp Arg Ala Val Ala Arg Arg Asn Val Val Leu Ser Arg Met Leu 195 200 205 Asp Glu Gly Tyr He Thr Gin Gin Gin Phe Asp Gin Thr Arg Thr Glu 210 215 220 Ala He Asn Ala Asn Tyr His Ala Pro Glu He Ala Phe Ser Ala Pro 225 230 235 240 Tyr Leu Ser Glu Met Val Arσ Gin Glu Met Tyr Asn Arg Tyr Gly Glu 245 250 255 Ser Ala Tyr Glu Asp Gly Tyr Arg He Tyr Thr Thr He Thr Arg Lys 260 265 270 Val Gin Gin Ala Ala Gin Gin Ala Val Arg Asn Asn Val Leu Asp Tyr 275 280 285 Asp Met Arg His Gly Tyr Arg Gly Pro Ala Asn Val Leu Trp Lys Val 290 295 300 Gly Glu Ser Ala Trp Asp Asn Asn Lys He Thr Asp Thr Leu Lys Ala 305 310 315 320 Leu Pro Thr Tyr Gly Pro Leu Leu Pro Ala Ala Val Thr Ser Ala Asn 325 330 335 Pro Gin Gin Ala Thr Ala Met Leu Ala Asp Gly Ser Thr Val Ala Leu 340 345 350 Ser Met Glu Gly Val Arg Trp Ala Arg Pro Tyr Arg Ser Asp Thr Gin 355 360 365 Gin Gly Pro Thr Pro Arg Lys Val Thr Asp Val Leu Gin Thr Gly Gin 370 375 380 Gin He Trp Val Arg Gin Val Gly Asp Ala Trp Trp Leu Ala Gin Val 385 390 395 400 Pro Glu Val Asn Ser Ala Leu Val Ser He Asn Pro Gin Asn Gly Ala 405 410 415 Val Met Ala Leu Val Gly Gly Phe Asp Phe Asn Gin Ser Lys Phe Asn 420 425 430 Arg Ala Thr Gin Ala Leu Arg Gin Val Gly Ser Asn He Lys Pro Phe 435 440 445 Leu Tyr Thr Ala Ala Met Asp Lys Gly Leu Thr Leu Ala Ser Met Leu 450 455 460 Asn Asp Val Pro He Ser Arg Trp Asp Ala Ser Ala Gly Ser Asp Trp 465 470 475 480 Gin Pro Lvs Asn Ser Pro Pro Gin Tyr Ala Gly Pro He Arg Leu Arg 485 490 495 Gin Gly Leu Gly Gin Ser Lys Asn Val Val Met Val Arg Ala Met Arg 500 505 510 Ala Met Gly Val Asp Tyr Ala Ala Glu Tyr Leu Gin Arg Phe. Gly Phe 515 520 525 Pro Ala Gin Asn He Val His Thr Glu Ser Leu Ala Leu Gly Ser Ala 530 535 540 Ser Phe Thr Pro Met Gin Val Ala Arα Gly Tyr Ala Val Met Ala Asn 545 550 555 560 Gly Gly Phe Leu Val Asp Pro Trp Phe He Ser Lvs He Glu Asn Asp 565 570 575 Gin Gly Gly Val He Phe Glu Ala Lys Pro Lys Val Ala Cvs Pro Glu 580 585 590 Cys Asp He Pro Val He Tyr Gly Asp Thr Gin Lys Ser Asn Val Leu 595 600 605 Glu Asn Asn Asp Val Glu Asp Val Ala He Ser Arg Glu Gin Gin Asn 610 615 620 Val,Ser Val Pro Met Pro Gin Leu Glu Gin Ala Asn Gin Ala Leu Val 625 630 635 640 Ala Lys Thr Gly Ala Gin Glu Tyr Ala Pro His Val He Asn Thr Pro 645 650 655 Leu Ala Phe Leu He Lys Ser Ala Leu Asn Thr Asn He Phe Gly Glu 660 665 670 Pro Gly Trp Gin Gly Thr Gly Trp Arg Ala Gly Arg Asp Leu Gin Arg 675 680 685 Arg Asp He Gly Gly Lys Thr Gly Thr Thr Asn Ser Ser Lys Asp Ala 690 695 700 WO96/16082 _ 5 ^_ PCT/SE9500761 Trp Phe Ser Gly Tyr Gly Pro Gly Val Val Thr Ser Val Trp He Gly 705 710 715 720 Phe Asp Asp His Arg Arg Asn Leu Gly His Thr Thr Ala Ser Gly Ala 725 730 735 He Lys Asp Gin He Ser Gly Tyr Glu Gly Gly Ala Lys Ser Ala Gin 740 745 750 Pro Ala Trp Asp Ala Tyr Met Lys Ala Val Leu Glu Gly Val Pro Glu 55 760 765 Gin Pro Leu Thr Pro Pro Pro Gly He Val Thr Val Asn He Asp Arg 770 775 780 Ser Thr Gly Gin Leu Ala Asn Gly Gly Asn Ser Arg Glu Glu Tyr Phe 785 790 795 800 He Glu Gly Thr Gin Pro Thr Gin Gin Ala Val His Glu Val Gly Thr 805 810 815 Thr He He Asp Asn Gly Glu Ala Gin Glu Leu Leu 820 825 (2; INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2472 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (B) STRAIN: DH5 alpha (vii) IMMEDIATE SOURCE: (A) LIBRARY: PCR cloning (B) CLONE: pARC 0556 Soluble PBP IB (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2472 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 1..2469 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: ATG GCC GGG AAT GAC CGC GAG CCA ATT GGA CGC AAA GGG AAA CCG ACG 48 Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lys Pro Thr 1 5 10 15 CGT CCG GTC AAA CAA AAG GTA AGC CGT CGT CGT TAC GAA GAT GAC GAT 96 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 GAT TAC GAC GAT TAT GAT GAC TAT GAG GAT GAA GAA CCG ATG CCG CGC 144 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 AAA GGT AAG GGC AAA GGC AAA GGG CGT AAG CCT CGT GGC AAA CGC GGC 192 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Gly 50 55 60 TCG ATC GAT CAA AAA ATT CGT AGC CGT ATT GAT GGC AAG GTC TGG CAA 240 Ser He Asp Gin Lys He Arg Ser Arg He Asp Gly Lys Val Trp Gin 65 70 75 80 CTC GCT GCG GCA GTT TAT GGC CGA ATG GTC AAT CTT GAG CCA GAC ATG 288 Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn Leu Glu Pro Asp Met 85 90 95 ACC ATC AGC AAG AAC GAG ATG GTG AAG CTG CTG GAG GCG ACC CAG TAT 336 Thr He Ser Lys Asn Glu Met Val Lys Leu Leu Glu Ala Thr Gin Tyr 100 105 110 CGT CAG GTG TCG AAA ATG ACC CGT CCT GGC GAA TTT ACC GTG CAG GCC 384 Arg Gin Val Ser Lys Met Thr Arg Pro Gly Glu Phe Thr Val Gin Ala 115 120 125 AAC AGC ATT GAG ATG ATT CGC CGT CCG TTT GAT TTC CCG GAC AGT AAA 432 Asn Ser He Glu Met He Arg Arg Pro Phe Asp Phe Pro Asp Ser Lys 130 135 140 GAA GGA CAG GTG CGC GCG CGT CTG ACC TTT GAT GGC GAT CAT CTG GCG 480 Glu Glv Gin Val Arg Ala Arg Leu Thr Phe Asp Glv Asp His Leu Ala 145 150 155 160 ACG ATC GTC AAT ATG GAG AAC AAC CGT CAG TTC GGT TTC TTC CGT CTT 528 Thr He Val Asn Met Glu Asn Asn Arg Gin Phe Gly Phe Phe Arg Leu 165 170 175 GAT CCG CGT CTG ATC ACC ATG ATC TCT TCG CCA AAC GGT GAG CAG CGT 576 Asp Pro Arg Leu He Thr Met He Ser Ser Pro Asn Gly Glu Gin Arg 180 185 190 CTG TTT GTG CCG CGC AGT GGT TTC CCG GAT TTG CTG GTG GAT ACT TTG 624 Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu Leu Val Asp Thr Leu 195 200 205 CTG GCG ACA GAA GAC CGT CAT TTT TAC GAG CAT GAT GGA ATC AGT CTC 672 Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His Asp Gly He Ser Leu 210 215 220 TAC TCA ATC GGA CGT GCG GTG CTG GCA AAC CTG ACC GCC GGA CGC ACG 720 Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu Thr Ala Gly Arg Thr 225 230 235 240 GTA CAG GGT GCG AGT ACG CTG ACG CAA CAG CTG GTG AAA AAC CTG TTC 768 Val Gin Gly Ala Ser Thr Leu Thr Gin Gin Leu Val Lys Asn Leu Phe 245 250 255 CTC TCC AGC GAG CGT TCT TAC TGG CGT AAA GCG AAC GAA GCT TAC ATG 816 Leu Ser Ser Glu Arg Ser Tyr Trp Arg Lys Ala Asn Glu Ala Tyr Met 260 265 270 GCG CTG ATC ATG GAC GCG CGT TAC AGC AAA GAC CGT ATT CTT GAG CTG 864 Ala Leu He Met Asp Ala Arg Tyr Ser Lys Asp Arg He Leu Glu Leu 275 280 285 TAT ATG AAC GAG GTG TAT CTC GGT CAG AGC GGC GAC AAC GAA ATC CGC 912 Tyr Met Asn Glu Val Tyr Leu Gly Gin Ser Gly Asp Asn Glu He Arg 290 295 300 GGC TTC CCG CTG GCA AGC TTG TAT TAC TTT GGT CGC CCG GTA GAA GAG 960 Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly Arg Pro Val Glu Glu 305 310 315 320 CTA AGC CTC GAC CAG CAG GCG CTG TTA GTC GGT ATG GTG AAA GGG GCG 1008 Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly Met Val Lvs Gly Ala 325 330 335 TCC ATC TAC AAC CCG TGG CGT AAC CCA AAA CTG GCG CTG GAG CGA CGT 1056 Ser He Tyr Asn Pro Trp Arg Asn Pro Lys Leu Ala Leu Glu Arg Arg 340 345 350 AAT CTG GTG CTG CGT CTG CTG CAA CAG CAA CAG ATT ATT GAT CAA GAA 1104 Asn Leu Val Leu Arg Leu Leu Gin Gin Gin Gin He He Asp Gin Glu 355 360 365 CTC TAT GAC ATG TTG AGT GCC CGT CCG CTG GGG GTT CAG CCG CGC GGT 1152 Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly Val Gin Pre Arg Gly 370 375 380 GGG GTG ATC TCT CCT CAG CCA GCC TTT ATG CAA CTG GTG CGT CAG GAG 1200 Gly Val He Ser Pro Gin Pro Ala Phe Met Gin Leu Val Arα Gin Glu 385 390 395 400 CTG CAG GCA AAA CTG GGC GAT AAG GTA AAA GAT CTC TCC GGC GTG AAG 1248 Leu Gin Ala Lys Leu Gly Asp Lys Val Lys Asp Leu Ser Glv Val Lys 405 410 415 ATC TTC ACT ACC TTT GAC TCG GTG GCC CAG GAC GCG GCA GAA AAA GCC 1296 He Phe Thr Thr Phe Asp Ser Val Ala Gin ASD Ala Ala G.-i Lvs Ala 420 425 431 GCC GTG GAA GGC ATT CCG GCA CTG AAG AAA CAG CGT AAG TTG AGC GAT 1344 Ala Val Glu Gly He Pro Ala Leu Lys Lys Gin Arg Lys L -i Ser Asp 435 440 445 CTT GAA ACT GCG ATT GTG GTC GTC GAC CGC TTT AGT GGT GAA GTT CGT 1392 Leu Glu Thr Ala He Val Val Val Asp Arg Phe Ser Gly Glu Val Arg 450 455 460 GCG ATG GTC GGA GGT TCT GAG CCG CAG TTT GCG GGC TAC AAC CGT GCG 1440 Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala Gly Tyr Asr. Arg Ala 465 470 475 480 ATG CAG GCG CGT CGT TCG ATT GGT TCC CTT GCA AAA CCA GCG ACT TAT 1488 Met Gin Ala Arg Arg Ser He Gly Ser Leu Ala Lys Pro Ala Thr Tyr 485 490 495 CTG ACG GCC TTA AGC CAG CCG AAA ATC TAT CGT CTG AAT ACG TGG ATT 1536 Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg Leu Asn Thr Trp He 500 505 51! GCG GAT GCG CCA ATT GCG CTG CGT CAG CCG AAT GGC CAG GTC TGG TCA 1584 Ala Asp Ala Pro He Ala Leu Arg Gin Pro Asn Glv Gin Val Trp Ser 515 520 525 CCG CAG AAT GAT GAC CGT CGT TAT AGC GAA AGC GGC AGA GTG ATG CTG 1632 Pro Gin Asn Asp Asp Arg Arg Tyr Ser Glu Ser Gly Arg Val Met Leu 530 535 540 GTG GAT GCG TTG ACC CGT TCG ATG AAC GTG CCG ACG GTA AAT CTG GGG 1630 Val Asp Ala Leu Thr Arg Ser Met Asn Val Pro Thr Val Asr. Leu Gly 545 550 555 560 ATG GCG CTG GGG CTG CCT GCG GTT ACG GAG ACC TGG ATT AAA CTG GGC 1728 Met Ala Leu Gly Leu Pro Ala Val Thr Glu Thr Trp He Lys Leu Gly 565 570 575 GTA CCG AAA GAT CAG TTG CAT CCG GTT CCG GCA ATG CTG CTG GGG GCG 1776 Val Pro Lys Asp Gin Leu His Pro Val Pro Ala Met Leu Leu Gly Ala 580 585 59: TTG AAC TTA ACG CCA ATC GAA GTG GCG CAG GCA TTC CAG ACC ATC GCC 1824 Leu Asn Leu Thr Pro He Glu Val Ala Gin Ala Phe Gin Thr He Ala 595 600 605 AGC GGT GGT AAC CGT GCA CCG CTT TCT GCG CTG CGT TCG GTA ATC GCG 1872 Ser Gly Gly Asn Arg Ala Pro Leu Ser Ala Leu Arg Ser Val He Ala 610 615 620 GAA GAT GGC AAA GTG CTG TAT CAG AGC TTC CCG CAG GCG GAA CGC GCT 1920 Glu Asp Gly Lys Val Leu Tyr Gin Ser Phe Pro Gin Ala Glu Arg Ala 625 630 635 640 GTT CCG GCG CAG GCG GCG TAT CTG ACA CTA TGG ACC ATG CAG CAG GTG 1968 Val Pro Ala Gin Ala Ala Tyr Leu Thr Leu Trp Thr Met Gin Gin Val 645 650 655 GTA CAA CGC GGT ACG GGT CGT CAG CTT GGG GCG AAA TAC CCG AAC CTG 2016 Val Gin Arg Gly Thr Gly Arg Gin Leu Gly Ala Lys Tyr Pro Asn Leu 660 665 670 CAT CTG GCA GGG AAA ACA GGG ACT ACC AAC AAT AAC GTA GAT ACC TGG 2064 His Leu Ala Gly Lys Thr Gly Thr Thr Asn Asn Asn Val Asp Thr Trp 675 680 685 TTT GCG GGC ATT GAC GGC AGC ACG GTG ACC ATC ACC TGG GTC GGC CGT 2112 Phe Ala Glv He Asp Gly Ser Thr Val Thr He Thr Trp Val Glv Arσ 690 * 695 700 GAT AAC AAC CAG CCG ACC AAA CTG TAT GGT GCC AGC GGG GCA ATG TCG 2160 Asp Asn Asn Gin Pro Thr Lys Leu Tyr Gly Ala Ser Gly Ala Met Ser 705 710 715 720 ATT TAT CAG CGT TAT CTG GCT AAC CAG ACG CCA ACG CCG CTG AAT CTT 2203 He Tyr Gin Arg Tyr Leu Ala Asn Gin Thr Pro Thr Pro Leu Asn Leu 725 730 735 GTT CCG CCA GAA GAT ATT GCA GAT ATG GGC GTG GAC TAC GAC GGC AAC 2256 Val Pro Pro Glu Asp He Ala Asp Met Gly Val Asp Tyr Asp Gly Asn 740 745 750 TTT GTT TGC AGC GGT GGC ATG CGT ATC TTG CCG GTC TGG ACC AGC GAT 2304 Phe Val Cys Ser Gly Gly Met Arg He Leu Pre Val Trp Thr Ser Asp 755 760 765 CCG CAA TCG CTG TGC CAG CAG AGC GAG ATG CAG CAG CAG CCG TCA GGC 2352 Pro Gin Ser Leu Cys Gin Gin Ser Glu Met Glr. Gin Gin Pro Ser Gly 770 775 780 AAT CCG TTT GAT CAG TCT TCT CAG CCG CAG CAA CAG CCG CAA CAG CAA 2 00 Asn Pro Phe Asp Gin Ser Ser Gin Pro Gin Gir. Gin Pro Gin Gin Gin 785 790 79; 300 CCT GCT CAG CAA GAG CAG AAA GAC AGC GAC GGT GTA GCC GGT TGG ATC 2443 Pro Ala Gin Gin Glu Gin Lys Asp Ser Asp Glv Val Ala Gly Trp He 805 810 815 AAG GAT ATG TTT GGT AGT AAT TA 2472 Lys Asp Met Phe Gly Ser Asn 820 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 823 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear O96/16082 _ fi3 _ (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lys Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Gly 50 55 60 Ser He Asp Gin Lys He Arg Ser Arg He Asp Gly Lys Val Trp Gin 65 70 75 80 Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn Leu Glu Pro Asp Met 85 90 95 Thr He Ser Lys Asn Glu Met Val Lys Leu Leu Glu Ala Thr Gin Tyr 100 105 110 Arσ Gin Val Ser Lvs Met Thr Arσ Pro Glv Glu Phe Thr Val Gin Ala 115 * 120 125 Asn Ser He Glu Met He Arg Arg Pro Phe Asp Phe Pro Asp Ser Lys 130 135 140 Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp Gly Asp His Leu Ala 145 150 155 160 Thr He Val Asn Met Glu Asn Asn Arg Gin Phe Gly Phe Phe Arg Leu 165 170 175 Asp Pro Arg Leu He Thr Met He Ser Ser Pro Asn Gly Glu Gin Arg 180 185 190 Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu Leu Val Asp Thr Leu 195 200 205 Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His Asp Gly He Ser Leu 210 215 220 Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu Thr Ala Gly Arg Thr 225 230 235 240 Val Gin Gly Ala Ser Thr Leu Thr Gin Gin Leu Val Lys Asn Leu Phe 245 250 255 Leu Ser Ser Glu Arg Ser Tvr Trp Arg Lys Ala Asn Glu Ala Tyr Met 260 265 270 Ala Leu He Met Asp Ala Arg Tyr Ser Lys Asp Arg He Leu Glu Leu 275 280 285 Tyr Met Asn Glu Val Tyr Leu Gly Gin Ser Gly Asp Asn Glu He Arg 290 295 300 Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly Arg Pro Val Glu Glu 305 310 315 320 Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly Met Val Lys Gly Ala 325 330 335 Ser He Tyr Asn Pr Trp Arg Asn Pro Lys Leu Ala Leu Glu Arg Arg 340 345 350 Asn Leu Val Leu Arg Leu Leu Gin Gin Gin Gin He He Asp Gin Glu 355 360 365 Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly Val Gin Pro Arg Gly 370 375 380 Gly Val He Ser Pro Gin Pro Ala Phe Met Gin Leu Val Arg Gin Glu 385 390 395 400 Leu Gin Ala Lys Leu Gly Asp Lys Val Lys Asp Leu Ser Gly Val Lys 405 410 415 He Phe Thr Thr Phe Asp Ser Val Ala Gin Asp Ala Ala Glu Lys Ala 420 425 430 Ala Val Glu Gly He Pro Ala Leu Lys Lys Gin Arg Lys Leu Ser Asp 435 440 445 Leu Glu Thr Ala He Val Val Val Asp Arg Phe Ser Gly Glu Val Arg 450 455 460 Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala Gly Tyr Asn Ara Ala 465 470 475 " 430 Met Gin Ala Arg Arg Ser He Gly Ser Leu Ala Lys Pro Ala Thr Tyr 485 490 495 Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg Leu Asn Thr Trp He 500 505 510 Ala Asp Ala Pro He Ala Leu Arg Gin Pro Asn Gly Gin Val Trp Ser 515 520 525 Pro Gin Asn Asp Asp Arg Arg Tyr Ser Glu Ser Gly Arg Val Met Leu 530 535 540 Val Asp Ala Leu Thr Arg Ser Met Asn Val Pro Thr Val Asn Leu Gly 545 550 555 560 Met Ala Leu Glv Leu Pro Ala Val Thr Glu Thr Trp He Lvs Leu Gly 565 570 575 Val Pro Lys Asp Gin Leu His Pro Val Pro Ala Met Leu Leu Gly Ala 580 585 590 Leu Asn Leu Thr Pro He Glu Val Ala Gin Ala Phe Gin Thr He Ala 595 600 605 Ser Gly Gly Asn Arg Ala Pro Leu Ser Ala Leu Arg Ser Val He Ala 610 615 620 Glu Asp Gly Lys Val Leu Tyr Gin Ser Phe Pro Gin Ala Glu Arg Ala 625 630 635 640 Val Pro Ala Gin Ala Ala Tyr Leu Thr Leu Trp Thr Met Gin Gin Val 645 650 655 Val Gin Arg Gly Thr Gly Arg Gin Leu Gly Ala Lys Tyr Pro Asn Leu 660 665 670 His Leu Ala Gly Lys Thr Gly Thr Thr Asn Asn Asn Val Asp Thr Trp 675 680 685 Phe Ala Gly He Asp Gly Ser Thr Val Thr He Thr Trp Val Gly Arg 690 695 700 Asp Asn Asn Gin Pro Thr Lys Leu Tyr Gly Ala Ser Gly Ala Met Ser 705 710 715 720 He Tyr Gin Arg Tyr Leu Ala Asn Gin Thr Pro Thr Pro Leu Asn Leu 725 730 735 Val Pro Pro Glu Asp He Ala Asp Met Gly Val Asp Tyr Asp Gly Asn 740 745 750 Phe Val Cys Ser Gly Gly Met Arg He Leu Pro Val Trp Thr Ser Asp 755 760 765 Pro Gin Ser Leu Cys Gin Gin Ser Glu Met Gin Gin Gin Pro Ser Gly 770 775 780 Asn Pro Phe Asp Gin Ser Ser Gin Pro Gin Gin Gin Pro Gin Gin Gin 785 790 795 800 Pro Ala Gin Gin Glu Gin Lys Asp Ser Asp Gly Val Ala Gly Trp He 805 810 815 Lys Asp Met Phe Gly Ser Asn 820 (2) INFORMATION FOR SEQ ID NO: 5: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2049 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Streptococcus pneumoniae (B) STRAIN: PM 1 (vii) IMMEDIATE SOURCE: (A) LIBRARY: PCR cloning (B) CLONE: pARC 0512 Soluble PBP 1A del 38 ( I ) FEATURE: (A) NAME, KEY: CDS (B) LOCATION: 1..2049 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 1..2046 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATG GCT CCT AGC CTA TCC GAG AGT AAA CTA GTT GCA ACA ACT TCT AGT 48 Met Ala Pro Ser Leu Ser Glu Ser Lys Leu Val Ala Thr Thr Ser Ser 1 5 10 15 AAA ATC TAC GAC AAT AAA AAT CAA CTC ATT GCT GAC TTG GGT TCT GAA 96 Lys He Tyr Asp Asn Lys Asn Gin Leu He Ala Asp Leu Gly Ser Glu 20 25 30 CGC CGC GTC AAT GCC CAA GCT AAT GAT ATT CCC ACA GAT TTG GTT AAG 144 Arg Arg Val Asn Ala Gin Ala Asn Asp He Pro Thr Asp Leu Val Lys 35 40 45 GCA ATC GTT TCT ATC GAA GAC CAT CGC TTC TTC GAC CAC AGG GGG ATT 192 Ala He Val Ser He Glu Asp His Arg Phe Phe Asp His Arg Gly He 50 55 60 GAT ACC ATC CGT ATC CTG GGA GCT TTC TTG CGC AAT CTG CAA AGC AAT 240 Asp Thr He Arg He Leu Gly Ala Phe Leu Arg Asn Leu Gin Ser Asn 65 70 75 80 TCC CTC CAA GGT GGA TCA GCT CTC ACT CAA CAG TTG ATT AAG TTG ACT 283 Ser Leu Gin Gly Gly Ser Ala Leu Thr Gin Gin Leu He Lys Leu Thr 85 90 95 TAC TTT TCA ACT TCG ACT TCC GAC CAG ACT ATT TCT CGT AAG GCT CAG 336 Tyr Phe Ser Thr Ser Thr Ser Asp Gin Thr He Ser Arg Lys Ala Gin 100 105 110 GAA GCT TGG TTA GCG ATT CAG TTA GAA CAA AAA GCA ACC AAG CAA GAA 384 Glu Ala Trp Leu Ala He Gin Leu Glu Gin Lys Ala Thr Lys Gin Glu 115 120 125 ATC TTG ACC TAC TAT ATA AAT AAG GTC TAC ATG TCT AAT GGG AAC TAT 432 He Leu Thr Tyr Tyr He Asn Lys Val Tyr Met Ser Asn Gly Asn Tyr 130 135 140 GGA ATG CAG ACA GCA GCT CAA AAC TAC TAT GGT AAA GAC CTC AAT AAT 480 Gly Met Gin Thr Ala Ala Gin Asn Tyr Tyr Gly Lvs ASD Leu Asn Asn 145 150 155 ' 160 TTA AGT TTA CCT CAG TTA GCC TTG CTG GCT GGA ATG CCT CAG GCA CCA 528 Leu Ser Leu Pro Gin Leu Ala Leu Leu Ala Gly Met Pro Gin Ala Pro 165 170 175 AAC CAA TAT GAC CCC TAT TCA CAT CCA GAA GCA GCC CAA GAC CGC CGA 576 Asn Gin Tyr Asp Pro Tyr Ser His Pro Glu Ala Ala Gin Asp _Arg Arg 180 185 150 AAC TTG GTC TTA TCT GAA ATG AAA AAT CAA GGC TAC ATC TCT GCT GAA 624 Asn Leu Val Leu Ser Glu Met Lvs Asn Gin Gly Tvr He Ser Ala Glu 195 200 " 205 CAG TAT GAG AAA GCA GTC AAT ACA CCA ATT ACT GAT GGG CTA CAA AGT 672 Gin Tvr Glu Lys Ala Val Asn Thr Pro He Thr Asp Gly Leu Gin Ser 210 215 220 CTC AAA TCA GCA AGT AAT TAC CCT GCT TAC ATG GAT AAT TAC CTC AAG 720 Leu Lys Ser Ala Ser Asn Tyr Pro Ala Tyr Met Asp Asn Tvr Leu Lys 225 230 235 ' 240 GAA GTC ATC AAT CAA GTT GAA GAA GAA ACA GGC TAT AAC CTA CTC ACA 768 Glu Val He Asn Gin Val Glu Glu Glu Thr Gly Tyr Asn Leu Leu Thr 245 250 255 ACT GGG ATG GAT GTC TAC ACA AAT GTA GAC CAA GAA GCT CAA AAA CAT 816 Thr Gly Met Asp Val Tyr Thr Asn Val Asp Gin Glu Ala Gin Lys His 260 265 270 CTG TGG GAT ATT TAC AAT ACA GAC GAA TAC GTT GCC TAT CCA GAC GAT 864 Leu Trp Asp He Tyr Asn Thr Asp Glu Tyr Val Ala Tyr Pro Asp Asp 275 280 285 GAA TTG CAA GTC GCT TCT ACC ATT GTT GAT GTT TCT AAC GGT AAA GTC 912 Glu Leu Gin Val Ala Ser Thr He Val Asp Val Ser Asn Gly Lys Val 290 295 300 ATT GCC CAG CTA GGA GCA CGC CAT CAG TCA AGT AAT GTT TCC TTC GGA 960 He Ala Gin Leu Gly Ala Arg His Gin Ser Ser Asn Val Ser Phe Gly 305 310 215 320 ATT AAC CAA GCA GTA.GAA ACA AAC CGC GAC TGG GGA TCA ACT ATG AAA 1008 He Asn Gin Ala Val v Glu Thr Asn Arg Asp Trp Gly Ser Thr Met Lys 325 330 335 CCG ATC ACA GAC TAT GCT CCT GCC TTG GAG TAC GGT GTC TAC GAG TCA 1056 Pro He Thr Asp Tyr Ala Pro Ala Leu Glu Tyr Gly Val Tyr Glu Ser 340 345 350 ACT GCC ACT ATC GTT CAC GAT GAG CCC TAT AAC TAC CCT GGG ACA AAT 1104 Thr Ala Thr He Val His Asp Glu Pro Tyr Asn Tyr Pro Gly Thr Asn 355 360 365 ACC CCT GTT TAT AAC TGG GAT AGG GGC TAC TTT GGC AAC ATC ACC TTG 1152 Thr Pro Val Tyr Asn Trp Asp Arg Gly Tyr Phe Gly Asn He Thr Leu 370 375 380 CAA TAC GCC CTG CAA CAA TCG CGA AAC GTC CCA GCC GTG GAA ACT CTA 1200 Gin Tyr Ala Leu Gin Gin Ser Arg Asn Val Pro Ala Val Glu Thr Leu 385 390 395 400 AAC AAG GTC GGA CTC AAC CGC GCC AAG ACT TTC CTA AAT GGT CTC GGA 1248 Asn Lys Val Glv Leu Asn Arg Ala Lys Thr Phe Leu Asn Gly Leu Gly 405 410 415 ATC GAC TAC CCA AGT ATT CAC TAC TCA AAT GCC ATT TCA AGT AAC ACA 1296 He Asp Tvr Pro Ser He His Tyr Ser Asn Ala He Ser Ser Asn Thr 420 425 430 ACC GAA TCA GAC AAA AAA TAT GGA GCA AGT AGT GAA AAG ATG GCT GCT 1344 Thr Glu Ser Asp Lys Lys Tyr Gly Ala Ser Ser Glu Lys Met Ala Ala 435 440 445 GCT TAC GCT GCC TTT GCA AAT GGT GGA ACT TAC TAT AAA CCA ATG TAT 1392 Ala Tyr Ala Ala Phe Ala Asn Gly Gly Thr Tyr Tyr Lys Pro Met Tyr 450 455 460 ATC CAT AAA GTC GTC TTT AGT GAT GGG AGT GAA AAA GAG TTC TCT AAT 1440 He His Lys Val Val Phe Ser Asp Gly Ser Glu Lys Glu Phe Ser Asn 465 470 475 480 GTC GGA ACT CGT GCC ATG AAA GAA ACG ACA GCC TAT ATG ATG ACC GAC 1433 Val Gly Thr Arg Ala Met Lys Glu Thr Thr Ala Tyr Met Met Thr Asp 485 -.90 495 ATG ATG AAA ACA GTC TTG AGT TAT GGA ACT GGA CGA AAT GCC TAT CTT 1536 Met Met Lys Thr Val Leu Ser Tyr Gly Thr Gly Arg Asn Ala Tyr Leu 500 505 510 GCT TGG CTC CCT CAG GCT GGT AAA ACA GGA ACC TCT AAC TAT ACA GAC 1534 Ala Trp Leu Pro Gin Ala Gly Lys Thr Gly Thr Ser Asn Tyr Thr Asp 515 520 525 GAG GAA ATT GAA AAC CAC ATC AAG ACC TCT CAA TTT GTA GCA CCT GAT 1632 Glu Glu He Glu Asn His He Lys Thr Ser Gin Phe Val Ala Pro Asp 530 535 540 GAA CTA TTT GCT GGC TAT ACG CGT AAA TAT TCA ATG GCT GTA TGG ACA 1630 Glu Leu Phe Ala Gly Tvr Thr Arg Lys Tvr Ser Met Ala Val Trp Thr 545 550 555 560 GGC TAT TCT AAC CGT CTG ACA CCA CTT GTA GGC AAT GGC CTT ACG GTC 1728 Gly Tyr Ser Asn Arg Leu Thr Pro Leu Val Gly Asn Gly Leu Thr Val 565 570 575 GCT GCC AAA GTT TAC CGC TCT ATG ATG ACC TAC CTG TCT GAA GGA AGC 1776 Ala Ala Lys Val Tyr Arg Ser Met Met Thr Tyr Leu Ser Glu Gly Ser 530 585 590 AAT CCA GAG GAT TGG AAT ATA CCA GAG GGG CTC TAC AGA AAT GGA GAA 1824 Asn Pro Glu Asp Trp Asn He Pro Glu Gly Leu Tvr Arg Asn Gly Glu 595 600 605 TTC GTA TTT AAA AAT GGT GCT CGT TCT ACG TGG AGC TCA CCT GCT CCA 1872 Phe Val Phe Lys Asn Gly Ala Arg Ser Thr Trp Ser Ser Pro Ala Pro 610 615 620 CAA CAA CCC CCA TCA ACT GAA AGT TCA AGC TCA TCA TCA GAT AGT TCA 1920 Gin Gin Pro Pro Ser Thr Glu Ser Ser Ser Ser Ser Ser Asp Ser Ser 625 630 635 640 ACT TCA CAG TCT AGC TCA ACC ACT CCA AGC ACA AAT AAT AGT ACG ACT 1968 Thr Ser Gin Ser Ser Ser Thr Thr Pro Ser Thr Asn Asn Ser Thr Thr 645 650 655 ACC AAT CCT AAC AAT AAT ACG CAA CAA TCA AAT ACA ACC CCT GAT CAA 2016 Thr Asn Pro Asn Asn Asn Thr Gin Gin Ser Asn Thr Thr Pro Asp Gin 660 665 670 CAA AAT CAG AAT CCT CAA CCA GCA CAA CCA TA 2049 Gin Asn Gin Asn Pro Gin Pro Ala Gin Pro 675 680 (2' INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 682 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Ala Pro Ser Leu Ser Glu Ser Lys Leu Val Ala Thr Thr Ser Ser 1 5 10 15 Lys He Tyr Asp Asn Lys Asn Gin Leu He Ala Aso Leu Gly Ser Glu 20 25 " 30 Ar Arg Val Asn Ala Gin Ala Asn Asp He Pro Thr Asp Leu Val Lys 35 40 45 Ala He Val Ser He Glu Asp His Arg Phe Phe Aso His Arg Gly He 50 55 61 Asp Thr He Arg He Leu Gly Ala Phe Leu Arg Asr. Leu Gin Ser Asn 65 70 75 80 Ser Leu Gin Gly Gly Ser Ala Leu Thr Gin Gin Leu He Lvs Leu Thr 85 90 95 Tyr Phe Ser Thr Ser Thr Ser Asp Gin Thr He Ser Arg Lys Ala Gin 100 105 110 Glu Ala Trp Leu Ala He Gin Leu Glu Gin Lys Ala Thr Lys Gin Glu 115 120 125 He Leu Thr Tyr Tyr He Asn Lys Val Tyr Met Ser Asn Gly Asn Tyr 130 135 140 Gly Met Gin Thr Ala Ala Gin Asn Tyr Tyr Gly Lys Asp Leu Asn Asn 145 150 155 160 Leu Ser Leu Pro Gin Leu Ala Leu Leu Ala Gly Met Pro Gin Ala Pro 165 170 175 Asn Gin Tyr Asp Pro Tyr Ser His Pro Glu Ala Ala Gin Asp Arg Arg 180 185 190 Asn Leu Val Leu Ser Glu Met Lys Asn Gin Gly Tyr He Ser Ala Glu 195 200 205 Gin Tyr Glu Lys Ala Val Asn Thr Pro He Thr Asp Gly Leu Gin Ser 210 215 220 Leu Lys Ser Ala Ser Asn Tyr Pro Ala Tyr Met Asp Asn Tyr Leu Lys 225 230 235 240 Glu Val He Asn Gin Val Glu Glu Glu Thr Gly Tyr Asn Leu Leu Thr 245 250 255 Thr Gly Met Asp Val Tyr Thr Asn Val Asp Gin Glu Ala Gin Lys His 260 265 270 Leu Trp Asp He Tyr Asn Thr Asp Glu Tyr Val Ala Tyr Pro Asp Asp 275 280 285 Glu Leu Gin Val Ala Ser Thr He Val Asp Val Ser Asn Gly Lys Val 290 295 300 He Ala Gin Leu Gly Ala Arg His Gin Ser Ser Asn Val Ser Phe Gly 305 310 315 320 He Asn Gin Ala Val Glu Thr Asn Arg Asp Trp Gly Ser Thr Met Lys 325 330 335 Pro He Thr Asp Tyr Ala Pro Ala Leu Glu Tyr Gly Val Tyr Glu Ser 340 345 350 Thr Ala Thr He Val His Asp Glu Pro Tyr Asn Tyr Pro Gly Thr Asn 355 360 365 Thr Pro Val Tyr Asn Trp Asp Arg Gly Tyr Phe Gly Asn He Thr Leu 370 375 380 Gin Tyr Ala Leu Gin Gin Ser Arg Asn Val Pro Ala Val Glu Thr Leu 385 390 395 400 Asn Lys Val Gly Leu Asn Arα Ala Lys Thr Phe Leu Asn Gly Leu Gly 405 410 415 He Asp Tyr Pro Ser He His Tyr Ser Asn Ala He Ser Ser Asn Thr 420 425 430 1r_r Glu Ser Asp Lys Lys Tyr Gly Ala Ser Ser Glu Lys Met Ala Ala 435 440 445 Ala Tyr Ala Ala Phe Ala Asn Glv Gly Thr Tvr Tyr Lys Pro Met Tyr 450 455 460 He His Lys Val Val Phe Ser Asp Gly Ser Glu Lys Glu Phe Ser Asn 465 470 475 480 Val Gly Thr Arg Ala Met Lys Glu Thr Thr Ala Tyr Met Met Thr Asp 485 490 495 Met Met Lys Thr Val Leu Ser Tyr Gly Thr Gly Arg Asn Ala Tyr Leu 500 505 510 Ala Trp Leu Pro Gin Ala Gly Lys Thr Gly Thr Ser Asn Tyr Thr Asp 515 520 525 Glu Glu He Glu Asn His He Lys Thr Ser Gin Phe Val Ala Pro Asp 530 535 540 O96/16082 _ 70- _ P Glu Leu Phe Ala Gly Tyr Thr Arg Lvs Tyr Ser Met Ala Val Trp Thr 545 550 555 560 Gly Tyr Ser Asn Arg Leu Thr Pro Leu Val Gly Asn Gly Leu Thr Val 565 570 575 Ala Ala Lys Val Tyr Arg Ser Met Met Thr Tyr Leu Ser Glu Gly Ser 580 585 590 Asn Pro Glu Asp Trp Asn He Pro Glu Gly Leu Tyr Arg Asn Gly Glu 595 600 605 Phe Val Phe Lys Asn Gly Ala Arg Ser Thr Trp Ser Ser Pro Ala Pro 610 615 620 Gin Gin Pro Pro Ser Thr Glu Ser Ser Ser Ser Ser Ser Asp Ser Ser 625 630 635 640 Thr Ser Gin Ser Ser Ser Thr Thr Pro Ser Thr Asn Asn Ser Thr Thr 645 650 655 Thr Asn Pro Asn Asn Asn Thr Gin Gin Ser Asn Thr Thr Pro Asp Gin 660 655 670 Gin Asn Gin Asn Pro Gin Pro Ala Gin Pro 675 680 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 844 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC0438 PEP IB QQAA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lys Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tvr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Glv 50 55 60 Trp Leu Trp Leu Leu Leu Lvs leu Ala He Val Phe Ala Val Leu He 65 70 " 75 80 Ala He Tyr Gly Val Tyr Leu Asp Gin Lys He Arg Ser Arg He Asp 85 90 95 Gly Lys Val Trp Gin Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn 100 105 110 Leu Glu Pro Asp Met Thr He Ser Lys Asn Glu Met Val Lys Leu Leu 115 120 125 Glu Ala Thr Gin Tyr Arg Gin Val Ser Lys Met Thr Arg Pro Gly Glu 130 135 140 Phe Thr Val Gin Ala Asn Ser He Glu Met He Arg Arg Pro Phe Asp 145 150 155 160 Phe Pro Asp Ser Lys Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp 165 170 175 Gly Asp His Leu Ala Thr He Val Asn Met Glu Asn Asn Arg Gin Phe 180 185 190 Gly Phe Phe Arg Leu Asp Pro Arg Leu He Thr Met He Ser Ser Pro 195 200 205 Asn Gly Glu Gin Arg Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu 210 215 220 Leu Val Asp Thr Leu Leu Ala Thr Glu Asp Ara His Phe Tyr Glu His 225 230 235 240 Asp Gly He Ser Leu Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu 245 250 255 Thr Ala Gly Arα Thr Val Gin Gly Ala Ser Thr Leu Thr Ala Ala Leu 260 265 270 Val Lys Asn Leu Phe Leu Ser Ser Glu Arg Ser Tyr Trp Arg Lvs Ala 275 280 285 Asn Glu Ala Tyr Met Ala Leu He Met Asp Ala Arg Tyr Ser Lys Asp 290 295 300 Arg He Leu Glu Leu Tyr Met Asn Glu Val Tvr Leu Gly Gin Ser Gly 305 310 315 320 Asp Asn Glu He Arg Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly 325 330 335 Arg Pro Val Glu Glu Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly 340 345 350 Met Val Lys Gly Ala Ser He Tyr Asn Pro Tro Arg Asn Pro Lys Leu 355 360 * 365 Ala Leu Glu Arg Arg Asn Leu Val Leu Arg leu Leu Gin Gin Gin Gin 370 375 330 He He Asp Gin Glu Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly 385 390 3=5 400 Val Gin Pro Arg Gly Gly Val He Ser Pro Gin Pro Ala Phe Met Gin 405 410 415 Leu Val Arg Gin Glu Leu Gin Ala Lys Leu Gly Asp Lys Val Lys Asp 420 425 430 Leu Ser Gly Val Lys He Phe Thr Thr Phe ASD Ser Val Ala Gin Asp 435 440 445 Ala Ala Glu Lys Ala Ala Val Glu Gly He Pro Ala Leu Lys Lys Gin 450 455 460 Arg Lys Leu Ser Asp Leu Glu Thr Ala He Val Val Val Asp Arg Phe 465 470 475 480 Ser Gly Glu Val Arg Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala 4 485 490 495 Gly Tyr Asn Arg Ala Met Gin Ala Arg Arg Ser He Gly Ser Leu Ala 500 505 510 Lys Pro Ala Thr Tyr Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg 515 520 525 Leu Asn Thr Trp He Ala Asp Ala Pro He Ala Leu Arg Gin Pro Asn 530 535 540 Gly Gin Val Trp Ser Pro Gin Asn Asp Asp Arg Arg Tyr Ser Glu Ser 545 550 555 560 Gly Arg Val Met Leu Val Asp Ala Leu Thr Arg Ser Met Asn Val Pro 565 570 575 Thr Val Asn Leu Gly Met Ala Leu Gly Leu Pro Ala Val Thr Glu Thr 580 585 590 Trp He Lys Leu Gly Val Pro Lys Asp Gin Leu His Pro Val Pro Ala 595 600 605 Met Leu Leu Gly Ala Leu Asn Leu Thr Pro He Glu Val Ala Gin Ala 610 615 620 Phe Gin Thr He Ala Ser Gly Gly Asn Arg Ala Pro Leu Ser Ala Leu 625 630 635 640 Arg Ser Val He Ala Glu Asp Gly Lys Val Leu Tyr Gin Ser Phe Pro 645 650 655 Gin Ala Glu Arg Ala Val Pro Ala Gin Ala Ala Tyr Leu Thr Leu Trp 660 665 670 Thr Met Gin Gin Val Val Gin Arg Gly Thr Gly Arg Gin Leu Gly Ala 675 680 635 Lys Tyr Pro Asn Leu His Leu Ala Gly Lys Thr Gly Thr Thr Asn Asn 690 695 700 Asn Val Asp Thr Trp Phe Ala Gly He Asp Gly Ser Thr Val Thr He 705 710 715 720 Thr Trp Val Gly Arg Asp Asn Asn Gin Pro Thr Lys Leu Tyr Gly Ala 725 730 735 Ser Gly Ala Met Ser He Tyr Gin Arα Tyr Leu Ala Asn Gin Thr Pro 740 745 750 Thr Pro Leu Asn Leu Val Pro Pro Glu Asp He Ala Asp Met Gly Val 755 760 765 Asp Tyr Asp Gly Asn Phe Val Cys Ser Gly Gly Met Arg He Leu Pro 770 775 730 Val Trp Thr Ser Asp Pro Gin Ser Leu Cys Gin Gin Ser Glu Met Gin 785 790 795 300 Gin Gin Pro Ser Gly Asn Pro Phe Asp Gin Ser Ser Gin Pro Gin Gin 805 810 815 Gin Pro Gin Gin Gin Pro Ala Gin Gin Glu Gin Lys Asp Ser Asp Gly 820 825 830 Val Ala Gly Trp He Lys Asp Met Phe Gly Ser Asn 835 840 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 844 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC0468 PBP IB QQLL (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lys Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arσ 35 40 4Ξ Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Gly 50 55 60 Trp Leu Trp Leu Leu Leu Lys Leu Ala He Val Phe Ala Val Leu He 65 70 75 30 Ala He Tyr Gly Val Tyr Leu Asp Gin Lys He Arg Ser Arg He Asp 85 90 95 Gly Lys Val Trp Gin Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn 100 105 110 Leu Glu Pro Asp Met Thr He Ser Lys Asn Glu Met Val Lys Leu Leu 115 120 125 Glu Ala Thr Gin Tyr Arg Gin Val Ser Lys Met Thr Arg Pro Gly Glu 130 135 140 Phe Thr Val Gin Ala Asn Ser He Glu Met He Arg Arg Pro Phe Asp 145 150 155 160 Phe Pro Asp Ser Lys Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp 165 170 175 Gly Asp His Leu Ala Thr He Val Asn Met Glu Asn Asn Arg Gin Phe 180 185 190 Gly Phe Phe Arg Leu Asp Pro Arg Leu He Thr Met He Ser Ser Pro 195 200 205 Asn Gly Glu Gin Arg Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu 210 215 220 Leu Val Asp Thr Leu Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His 225 230 235 240 Asp Gly He Ser Leu Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu 245 250 255 Thr Ala Gly Arg Thr Val Gin Gly Ala Ser Thr Leu Thr Leu Leu Leu 260 265 270 Val Lys Asn Leu Phe Leu Ser Ser Glu Arg Ser Tyr Trp Arg Lys Ala 275 280 285 Asn Glu Ala Tyr Met Ala Leu He Met Asp Ala Arg Tyr Ser Lys Asp 290 295 300 Arg He Leu Glu Leu Tyr Met Asn Glu Val Tvr Leu Gly Gin Ser Gly 305 310 315 320 Asp Asn Glu He Arg Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly 325 330 335 Arg Pro Val Glu Glu Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly 340 345 350 Met Val Lys Gly Ala Ser He Tyr Asn Pro Trp Arg Asn Pro Lys Leu 355 360 365 Ala Leu Glu Arg Arg Asn Leu Val Leu Arg Leu Leu Gin Gin Gin Gin 370 375 330 He He Asp Gin Glu Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly 385 390 395 400 Val Gin Pro Arg Gly Gly Val He Ser Pro Gin Pro Ala Phe Met Gin 405 410 415 Leu Val Arg Gin Glu Leu Gin Ala Lys Leu Glv Asp Lys Val Lys Asp 420 425 430 Leu Ser Gly Val Lys He Phe Thr Thr Phe Asp Ser Val Ala Gin Asp 435 440 445 Ala Ala Glu Lys Ala Ala Val Glu Gly He Fro Ala Leu Lys Lys Gin 450 455 460 Arg Lys Leu Ser Asp Leu Glu Thr Ala He Val Val Val Asp Arg Phe 465 470 4~5 480 Ser Gly Glu Val Arg Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala 485 490 495 Gly Tyr Asn Arg Ala Met Gin Ala Arg Arg Ser He Glv Ser Leu Ala 500 505 510 Lys Pro Ala Thr Tyr Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg 515 520 525 Leu Asn Thr Trp He Ala Asp Ala Pro He Ala Leu Arg Gin Pro Asn 530 535 540 Gly Gin Val Trp Ser Pro Gin Asn Asp Asp Arg Arg Tvr Ser Glu Ser 545 550 555 " 560 Gly Arg Val Met Leu Val Asp Ala Leu Thr Arα Ser Met Asn Val Pro 565 570 575 Thr Val Asn Leu Gly Met Ala Leu Gly Leu Pro Ala Val Thr Glu Thr 580 585 590 Trp He Lys Leu Gly Val Pro Lys Asp Gin Leu His Pro Val Pro Ala 595 600 605 Met Leu Leu Gly Ala Leu Asn Leu Thr Pro He Glu Val Ala Gin Ala 610 615 620 Phe Gin Thr He Ala Ser Gly Gly Asn Arg Ala Pro Leu Ser Ala Leu 625 630 635 640 Arg Ser Val He Ala Glu Asp Gly Lys Val Leu Tyr Gin Ser Phe Pro 645 650 655 Gin Ala Glu Arg Ala Val Pro Ala Gin Ala Ala Tyr Leu Thr Leu Trp 660 665 670 Thr Met Gin Gin Val Val Gin Arg Gly Thr Gly Arg Gin Leu Gly Ala 675 680 685 Lys Tyr Pro Asn Leu His Leu Ala Gly Lys Thr Gly Thr Thr Asn Asn 690 695 700 Asn Val Asp Thr Trp Phe Ala Gly He Asp Gly Ser Thr Val Thr He 705 710 715 720 Thr Trp Val Gly Arg Asp Asn Asn Gin Pro Thr Lys Leu Tyr Gly Ala 725 730 735 Ser Gly Ala Met Ser He Tyr Gin Arg Tyr Leu Ala Asn Gin Thr Pro 740 745 750 Thr Pro Leu Asn Leu Val Pro Pro Glu Asp He Ala Asp Met Gly Val 755 760 765 Asp Tyr Asp Gly Asn Phe Val Cys Ser Gly Gly Met Arα He Leu Pro 770 775 780 Val Trp Thr Ser Asp Pro Gin Ser Leu Cys Gin Gin Ser Glu Met Gin 785 790 795 800 Gin Gin Pro Ser Gly Asn Pro Phe Asp Gin Ser Ser Gin Pro Gin Gin 805 810 815 Gin Pro Gin Gin Gin Pro Ala Gin Gin Glu Gin Lys Asp Ser Asp Gly 820 825 33C Val Ala Gly Trp He Lys Asp Met Phe Gly Ser Asn 835 840 (2) INFORMATION FOR SEQ ID NO: 9: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 836 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC0469 PBP IB del 8 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Met Ala Gly Asn Asp Arg Glu Pro He Glv Arg Lvs Gly Lys Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Gly 50 55 60 Trp Leu Trp Leu Leu Leu Lys Leu Ala He Val Phe Ala Val Leu He 65 70 75 80 Ala He Tyr Gly Val Tyr Leu Asp Gin Lys He Arg Ser Arg He Asp 85 90 95 Gly Lys Val Trp Gin Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn 100 105 110 Leu Glu Pro Asp Met Thr He Ser Lys Asn Glu Met Val Lys Leu Leu 115 120 125 Glu Ala Thr Gin Tyr Arg Gin Val Ser Lys Met Thr Arg Pro Gly Glu 130 135 140 Phe Thr Val Gin Ala Asn Ser He Glu Met He Arg Arg Pro Phe Asp 145 150 155 160 Phe Pro Asp Ser Lys Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp 165 170 175 Gly Asp His Leu Ala Thr He Val Asn Met Glu Asn Asn Arg Gin Phe 180 185 190 Gly Phe Phe Arg Leu Asp Pro Arg Leu He Thr Met He Ser Ser Pro 195 200 205 Asn Glv Glu Gin Arg Leu Phe Val Pro Arg Ser Glv Phe Pro Asp Leu 210 215 220 Leu Val Asp Thr Leu Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His 225 230 235 240 Asp Gly He Ser Leu Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu 245 250 255 Thr Ala Gly Arg Thr Val Gin Leu Val Lys Asn Leu Phe Leu Ser Ser 260 265 270 Glu Arg Ser Tyr Trp Arg Lys Ala Asn Glu Ala Tyr Met Ala Leu He 275 280 285 Met Asp Ala Arg Tyr Ser Lys Asp Arg He Leu Glu Leu Tyr Met Asn 290 295 30C Glu Val Tyr Leu Gly Gin Ser Gly Asp Asn Glu He Arg Gly Phe Pro 305 310 315 320 Leu Ala Ser Leu Tyr Tyr Phe Gly Arg Pro Val Glu Glu Leu Ser Leu 325 330 335 Asp Gin Gin Ala Leu Leu Val Gly Met Val Lvs Gly Ala Ser He Tyr 340 345 350 Asn Pro Trp Arg Asn Pro Lys Leu Ala Leu Glu Arg Arg Asn Leu Val 355 360 365 Leu Arg Leu Leu Gin Gin Gin Gin He He Asp Gin Glu Leu Tyr Asp 370 375 380 Met Leu Ser Ala Arg Pro Leu Gly Val Gin Pro Arg Gly Gly Val He 385 390 395 400 Ser Pro Gin Pro Ala Phe Met Gin Leu Val Arg Gin Glu Leu Gin Ala 405 410 415 Lys Leu Gly Asp Lys Val Lvs Asp Leu Ser Gly Val Lys He Phe Thr 420 425 430 Thr Phe Asp Ser Val Ala Gin Asp Ala Ala Glu Lys Ala Ala Val Glu 435 440 445 Gly He Pro Ala Leu Lys Lys Gin Arg Lys Leu Ser Asp Leu Glu Thr 450 455 460 Ala He Val Val Val Asp Arg Phe Ser Gly Glu Val Arg Ala Met Val 465 470 475 480 Gly Gly Ser Glu Pro Gin Phe Ala Gly Tyr Asn Arg Ala Met Gin Ala 485 490 495 Arg Arg Ser He Gly Ser Leu Ala Lys Pro Ala Thr Tyr Leu Thr Ala 500 505 510 Leu Ser Gin Pro Lys He Tyr Arg Leu Asn Thr Trp He Ala Asp Ala 515 520 525 Pro He Ala Leu Arg Gin Pro Asn Gly Gin Val Trp Ser Pro Gin Asn 530 535 540 Asp Asp Arg Arg Tyr Ser Glu Ser Gly Arg Val Met Leu Val Asp Ala 545 550 555 560 Leu Thr Arg Ser Met Asn Val Pro Thr Val Asn Leu Glv Met Ala Leu 565 570 57E Gly Leu Pro Ala Val Thr Glu Thr Trp He Lvs Leu Glv Val Pro Lys 580 585 590 Asp Gin Leu His Pro Val Pro Ala Met Leu Leu Gly Ala Leu Asn Leu 595 600 605 Thr Pro He Glu Val Ala Gin Ala Phe Gin Thr He Ala Ser Glv Gly 610 615 620 Asn Arg Ala Pro Leu Ser Ala Leu Arg Ser Val He Ala Glu Asp Gly 625 630 635 640 Lys Val Leu Tyr Gin Ser Phe Pro Gin Ala Glu Arg Ala Val Pro Ala 645 650 655 Gin Ala Ala Tyr Leu Thr Leu Trp Thr Met Gin Gin Val Val Gin Arg 660 665 670 Gly Thr Gly Arg Gin Leu Gly Ala Lys Tyr Pro Asn Leu His Leu Ala 675 680 685 Gly Lys Thr Gly Thr Thr Asn Asn Asn Val Asp Thr Trp Phe Ala Gly 690 695 700 He Asp Gly Ser Thr Val Thr He Thr Trp Val Gly Arσ Asp Asn Asn 705 710 715 720 Gin Pro Thr Lys Leu Tyr Gly Ala Ser Gly Ala Met Ser He Tyr Gin 725 730 735 Arg Tyr Leu Ala Asn Gin Thr Pro Thr Pro Leu Asn Leu Val Pro Pro 740 745 750 Glu Asp He Ala Asp Met Gly Val Asp Tyr Asp Gly Asn Phe Val Cys 755 760 765 Ser Gly Gly Met Arg He Leu Pro Val Trp Thr Ser Asp Pro Gin Ser 770 775 780 Leu Cys Gin G Ser Glu Met Gin Gin Gin Pro Ser Gly Asn Pro Phe 785 790 795 800 Asp Gin Ser Ser Gin Pro Gin Gin Gin Pro Gin Gin Gin Pro Ala Glr. 805 810 815 Gin Glu Gin Lys Asp Ser Asp Gly Val Ala Gly Trp He Lys Asp Met 820 825 830 Phe Gly Ser Asn 835 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 850 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC0 71 PBP 1A QQAA ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Lys Phe Val Lys Tyr Phe Leu He Leu Ala Val Cys Cys He Leu 1 5 10 15 Leu Gly Ala Gly Ser He Tyr Gly Leu Tyr Arg Tyr He Glu Pro Glr. 20 25 30 Leu Pro Asp Val Ala Thr Leu Lys Asp Val Arg Leu Gin He Pro Met 35 40 45 Gin He Tyr Ser Ala Asp Gly Glu Leu lie Ala Gin Tyr Glv Glu Lys 50 55 60 Arg Arg He Pro Val Thr Leu Asp Gin He Pro Pro Glu Met Val Lys 65 70 75 80 Ala Phe He Ala Thr Glu Asp Ser Arg Phe Tyr Glu His His Gly Val 85 90 95 Asp Pro Val Gly He Phe Arg Ala Ala Ser Val Ala Leu Phe Ser Glv 100 105 110 His Ala Ser Gin Gly Ala Ser Thr He Thr Ala Ala Leu Ala Arg Asr. 115 120 125 Phe Phe Leu Ser Pro Glu Arg Thr Leu Met Arg Lys He Lys Glu Val 130 135 140 Phe Leu Ala He Arg He Glu Gin Leu Leu Thr Lys Asp Glu He Leu 145 150 155 16. Glu Leu Tyr Leu Asn Lys He Tyr Leu Gly Tyr Arg Ala Tyr Gly Val 165 170 175 Gly Ala Ala Ala Gin Val Tyr Phe Gly Lys Thr Val Asp Gin Leu Thr 180 185 190 Leu Asn Glu Met Ala Val He Ala Gly Leu Pro Lys Ala Pro Ser Thr 195 200 205 Phe Asn Pro Leu Tyr Ser Met Asp Arg Ala Val Ala Arg Arg Asn Val 210 215 220 Val Leu Ser Arg Met Leu Asp Glu Gly Tyr He Thr Gin Gin Gin Phe 225 230 235 240 Asp Gin Thr Arg Thr Glu Ala He Asn Ala Asn Tyr His Ala Pro Glu 245 250 255 He Ala Phe Ser Ala Pro Tyr Leu Ser Glu Met Val Arα Gin Glu Met 260 265 270 Tyr Asn Arg Tyr Gly Glu Ser Ala Tyr Glu Asp Gly Tyr Arg He Tyr 275 280 285 Thr Thr He Thr Arg Lys Val Gin Gin Ala Ala Gin Gin Ala Val Arg 290 295 300 Asn Asn Val Leu Asp Tyr Asp Met Arg His Gly Tyr Arg Gly Pro Ala 305 310 315 320 Asn Val Leu Trp Lys Val Gly Glu Ser Ala Trp Asp Asn Asn Lys He 325 330 335 Thr Asp Thr Leu Lys Ala Leu Pro Thr Tyr Gly Pro Leu Leu Pro Ala 340 345 350 Ala Val Thr Ser Ala Asn Pro Gin Gin Ala Thr Ala Met Leu Ala Asp 355 360 3SΞ Gly Ser Thr Val Ala Leu Ser Met Glu Gly Val Arg Trp Ala Arg Pro 370 375 380 Tyr Arg Ser Asp Thr Gin Gin Gly Pro Thr Pro Arg Lvs Val Thr Asp 385 390 395 400 Val Leu Gin Thr Gly Gin Gin He Trp Val Arg Gin Val Gly Asp Ala 405 410 415 Trp Trp Leu Ala Gin Val Pro Glu Val Asn Ser Ala Leu Val Ser He 420 425 430 Asn Pro Gin Asn Gly Ala Val Met Ala Leu Val Gly Glv Phe Asp Phe 435 440 445 Asn Gin Ser Lys Phe Asn Arg Ala Thr Gin Ala Leu Arα Gin Val Gly 450 455 460 Ser Asn He Lys Pro Phe Leu Tyr Thr Ala Ala Met Asp Lys Glv Leu 465 470 475 * 480 Thr Leu Ala Ser Met Leu Asn Asp Val Pro He Ser Arg Trp Asp Ala 485 490 495 Ser Ala Gly Ser Asp Trp Gin Pro Lys Asn Ser Pro Pro Gin Tvr Ala 500 505 510 Gly Pro He Arg Leu Arg Gin Gly Leu Gly Gin Ser Lvs Asn Val Val 515 520 525 Met Val Arg Ala Met Arg Ala Met Gly Val Asp Tyr Ala Ala Glu Tvr 530 535 540 Leu Gin Arg Phe Gly Phe Pro Ala Gin Asn He Val His Thr Glu Ser 545 550 555 560 Leu Ala Leu Gly Ser Ala Ser Phe Thr Pro Met Gin Val Ala Arg Gly 565 570 575 Tyr Ala Val Met Ala Asn Gly Gly Phe Leu Val Asp Pro Trp Phe He 580 585 590 Ser Lys He Glu Asn Asp Gin Gly Gly Val He Phe Glu Ala Lys Pro 595 600 605 Lys Val Ala Cys Pro Glu Cys Asp He Pro Val He Tyr Gly Asp Thr 610 615 620 Gin Lys Ser Asn Val Leu Glu Asn Asn Asp Val Glu Asp Val Ala He 625 630 635 640 Ser Arg Glu Gin Gin Asn Val Ser Val Pro Met Pro Gin Leu Glu Gin 645 650 655 Ala Asn Gin Ala Leu Val Ala Lys Thr Gly Ala Gin Glu Tyr Ala Pro 660 665 670 His Val He Asn Thr Pro Leu Ala Phe Leu He Lys Ser Ala Leu Asn 675 680 685 Thr Asn He Phe Gly Glu Pro Gly Trp Gin Gly Thr Gly Trp Arg Ala 690 695 700 Gly Arg Asp Leu Gin Arg Arg Asp He Gly Gly Lys Thr Gly Thr Thr 705 710 715 720 Asn Ser Ser Lys Asp Ala Trp Phe Ser Gly Tvr Gly Pro Gly Val Val 725 730 * 735 Thr Ser Val Trp He Gly Phe Asp Asp His Arg Arg Asn Leu Gly His 740 745 750 Thr Thr Ala Ser Gly Ala He Lys Asp Gin He Ser Gly Tyr Glu Gly 755 760 765 Gly Ala Lys Ser Ala Gin Pro Ala Trp Asp Ala Tyr Met Lys Ala Val 770 775 780 Leu Glu Gly Val Pro Glu Gin Pro Leu Thr Pro Pro Pro Gly He Val 785 790 "95 800 Thr Val Asn He Asp Arg Ser Thr Gly Gin Leu Ala Asn Gly Gly Asn 805 810 815 Ser Arg Glu Glu Tyr Phe He Glu Gly Thr Gin Pro Thr Gin Gin Ala 820 825 830 Val His Glu Val Gly Thr Thr He He Asp Asn Gly Glu Ala Gin Glu 835 840 845 Leu Phe 850 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 553 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC 0592 truncated PBP IB (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lvs Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arα Gly Lys Arg Gly 50 55 60 Trp Leu Trp Leu Leu Leu Lys Leu Ala He Val Phe Ala Val Leu He 65 70 75 80 Ala He Tyr Gly Val Tyr Leu Asp Gin Lys He Arg Ser Arg He Asp 85 90 95 Gly Lys Val Trp Gin Leu Ala Ala Ala Val Tvr Gly Arg Met Val Asn 100 105 " 110 Leu Glu Pro Asp Met Thr He Ser Lys Asn Glu Met Val Lvs Leu Leu 115 120 125 Glu Ala Thr Gin Tyr Arg Gin Val Ser lys Met Thr Arg Pro Gly Glu 130 135 140 Phe Thr Val Gin Ala Asn Ser He Glu Met He Arg Arg Pro Phe Asp 145 150 155 160 Phe Pro Asp Ser Lys Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp 165 170 175 Gly Asp His Leu Ala Thr He Val Asn Met Glu Asn Asn Arg Gin Phe 180 185 190 Gly Phe Phe Arc ,eu Asp Pro Arg Leu He Thr Met lie Ser Ser Pro 155 200 205 Asn Gly Glu Gin Arg Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu 210 215 220 Leu Val ASD Thr Leu Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His 225 230 235 240 Asp Gly He Ser Leu Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu 245 250 255 Thr Ala Gly Arg Thr Val Gin Gly Ala Ser Thr Leu Thr Gin Gin Leu 260 265 270 Val Lys Asn Leu Phe Leu Ser Ser Glu Arg Ser Tvr Trp Arg Lys Ala 275 280 * 235 Asn Glu Ala Tyr Met Ala Leu He Met Asp Ala Arg Tvr Ser Lys Asp 290 295 300 Arg He Leu Glu Leu Tyr Met Asn Glu Val Tyr Leu Gly Gin Ser Gly 305 310 315 320 Asp Asn Glu He Arg Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly 325 330 335 Arg Pro Val Glu Glu Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly 340 345 350 Met Val Lys Gly Ala Ser He Tyr Asn Pro Trp Arg Asn Pro Lys Leu 355 % 360 365 Ala Leu Glu Arg Arg Asn Leu Val Leu Arg Leu Leu Gin Gin Gin Gin 370 375 380 He He Asp Gin Glu Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly 385 390 395 400 Val Gin Pro Arg Gly Gly Val He Ser Pro Gin Pro Ala Phe Met Gin 405 410 415 Leu Val Arg Gin Glu Leu Gin Ala Lys Leu Gly Asp Lys Val Lys Asp 420 425 430 Leu Ser Gly Val Lys He Phe Thr Thr Phe Asp Ser Val Ala Gin Asp 435 440 445 Ala Ala Glu Lys Ala Ala Val Glu Gly He Pro Ala Leu Lys Lys Gin 450 455 460 Arg Lys Leu Ser Asp Leu Glu Thr Ala He Val Val Val Asp Arg Phe 465 470 475 480 Ser Gly Glu Val Arg Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala 485 490 495 Gly Tyr Asn Arg Ala Met Gin Ala Arg Arg Ser He Gly Ser Leu Ala 500 505 510 Lys Pro Ala Thr Tyr Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg 515 520 525 Leu Asn Thr Trp He Ala Asp Ala Pro He Ala Leu Arg Gin Pro Asn 530 535 540 Glv Gin Val Trp Ser Pro Gin Asn Asp 545 550 (2' INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 532 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC 0593 truncated soluble PBP IB (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Ala Gly Asn Asp Arg Glu Pro He Gly Arg Lys Gly Lys Pro Thr 1 5 10 15 Arg Pro Val Lys Gin Lys Val Ser Arg Arg Arg Tyr Glu Asp Asp Asp 20 25 30 Asp Tyr Asp Asp Tyr Asp Asp Tyr Glu Asp Glu Glu Pro Met Pro Arg 35 40 45 Lys Gly Lys Gly Lys Gly Lys Gly Arg Lys Pro Arg Gly Lys Arg Gly 50 55 60 Ser He Asp Gin Lys He Arg Ser Arg He Asp Gly Lys Val Trp Gin 65 70 75 80 Leu Ala Ala Ala Val Tyr Gly Arg Met Val Asn Leu Glu Pro Asp Met 85 90 95 Thr He Ser Lys Asn Glu Met Val Lys Leu Leu Glu Ala Thr Gin Tyr 100 105 110 Arg Gin Val Ser Lys Met Thr Arg Pro Gly Glu Phe Thr Val Gin Ala 115 120 125 Asn Ser He Glu Met He Arg Arg Pro Phe Asp Phe Pro Asp Ser Lys 130 135 140 Glu Gly Gin Val Arg Ala Arg Leu Thr Phe Asp Gly Asp His Leu Ala 145 150 155 160 Thr He Val Asn Met Glu Asn Asn Arg Gin Phe Gly Phe Phe Arg Leu 165 170 175 Asp Pro Arg Leu He Thr Met He Ser Ser Pro Asn Gly Glu Gin Arg 180 185 190 Leu Phe Val Pro Arg Ser Gly Phe Pro Asp leu Leu Val Asp Thr Leu 195 200 205 Leu Ala Thr Glu Asp Arg His Phe Tyr Glu His Asp Gly He Ser Leu 210 215 220 Tvr Ser He Gly Arg Ala Val Leu Ala Asn Leu Thr Ala Gly Arg Thr 225 230 235 240 Val Gin Gly Ala Ser Thr Leu Thr Gin Gin Leu Val Lvs Asn Leu Phe 245 250 255 Leu Ser Ser Glu Arg Ser Tyr Trp Arg Lys Ala Asn Glu Ala Tyr Met 260 265 270 Ala Leu He Met Asp Ala Arg Tyr Ser Lys ASD Arα He Leu Glu Leu 275 280 ' " 285 Tvr Met Asn Glu Val Tyr Leu Gly Gin Ser Gly Asp Asn Glu He Arg 290 295 300 Glv Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly Arg Pro Val Glu Glu 305 310 315 320 Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly Met Val Lys Gly Ala 325 330 335 Ser He Tyr Asn Pro Trp Arg Asn Pro Lys leu Ala Leu Glu Arg Arg 340 345 350 Asn Leu Val Leu Arg Leu Leu Gin Gin Gin Gin He He Asp Gin Glu . 355 360 365 Leu Tyr Asp Met Leu Ser Ala Arg Pro Leu Gly Val Gin Pro Arg Gly 370 375 380 Gly Val He Ser Pro Gin Pro Ala Phe Met Gin Leu Val Arg Gin Glu 385 390 395 400 Leu Gin Ala Lys Leu Gly Asp Lys Val Lys Asp Leu Ser Gly Val Lys 405 410 415 He Phe Thr Thr Phe Asp Ser Val Ala Gin Asp Ala Ala Glu Lys Ala 420 425 430 Ala Val Glu Gly He Pro Ala Leu Lys Lys Gin Arg Lys Leu Ser Asp 435 440 445 Leu Glu Thr Ala He Val Val Val Asp Arg Phe Ser Gly Glu Val Arg 450 455 460 Ala Met Val Gly Gly Ser Glu Pro Gin Phe Ala Gly Tyr Asn Arg Ala 465 470 475 480 Met Gin Ala Arg Arg Ser He Gly Ser Leu Ala Lys Pro Ala Thr Tyr 485 490 495 Leu Thr Ala Leu Ser Gin Pro Lys He Tyr Arg Leu Asn Thr Trp He 500 505 510 Ala Asp Ala Pro He Ala Leu Arσ Gin Pro Asn Gly Gin Val Trp Ser 515 520 525 Pro Gin Asn Asp 530 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 159 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic ι (vi) ORIGINAL SOURCE: (A) ORGANISM: Escherichia coli (vii) IMMEDIATE SOURCE: (B) CLONE: pARC 0392 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Gly Glu Gin Arg Leu Phe Val Pro Arg Ser Gly Phe Pro Asp Leu Leu 1 5 10 15 Val Asp Thr Leu Leu Ala Thr Glu Asp Arg His Phe Tvr Glu His Asp 20 25 30 Gly He Ser Leu Tyr Ser He Gly Arg Ala Val Leu Ala Asn Leu Thr 35 40 45 Ala Gly Arg Thr Val Gin Gly Ala Ser Thr Leu Thr Gin Gin Leu Val 50 55 60 Lys Asn Leu Phe Leu Ser Ser Glu Arg Ser Tvr Trp Arg Lys Ala Asn 65 70 75 80 Glu Ala Tyr Met Ala Leu He Met Asp Ala Arg Tyr Ser Lys Asp Arg 85 90 95 He Leu Glu Leu Tyr Met Asn Glu Val Tyr Leu Gly Gin Ser Gly Asp 100 105 110 Asn Glu He Arg Gly Phe Pro Leu Ala Ser Leu Tyr Tyr Phe Gly Arg 115 120 125 Pro Val Glu Glu Leu Ser Leu Asp Gin Gin Ala Leu Leu Val Gly Met 130 135 140 Val Lys Gly Ala Ser He Tyr Asn Pro Trp Arg Asn Pro Lys Leu 145 150 155 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) For International Bureau use only I j This sheet was received by the International Bureau on: Authorized officer Form PCT RO/134 (July 1992) -87- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) The indications made below relate to the microorganism referred to in the description on page _ , line _ B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet j | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40667 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for al! designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed belowwill be submitted to the International Bureau later (specify the genσal nature o the indications eg., 'Accession Number of Deposit') For International Bureau use only j | This sheet was received by the International Bureau on: Authorized officer Form PCT RO/134 (July 1992) -88- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule \3bis) A. The indications made below relate to the microorganism referred to in the description on page 27 . line B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | j Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1 994 NCIMB 40665 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requesied that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to Ihe International Bureau later (specify the general nature ofthe indications eg., 'Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application I I This sheet was received by the International Bureau on: Authorized officer -n 3 5 ε Authorized officer Form PCT RO/134 (July 1992) -89- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 12-bis) A. The indications made below relate to the microorganism referred to in the description on page 29 , l ._in_,_e. 19 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40661 C. ADDITIONAL INDICATIONS (leave blank if not applicable) Tliis information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are net for all deήgnated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted lo the Intemalional Bureau later (specify the general nature of the indications eg., 'Accession Number of Deposit') For receiving Office use only For International Bureau use only This sheet was received with the international application I I This sheet was received by the International Bureau on: Authorized officer sir Authorized officer Form PCT/RO/134 Jul 1992 -90- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13-Hs) A. The indications made below relate to the microorganism referred to in the description on page 29 . line 23 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40662 C. ADDl ' l lONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet | | In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications ar na for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if na applicable) The indications listed below ill be submitted to the International Bureau later (specify the general nature of the indications eg„ 'Accession Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application | I This sheet was received by the International Bureau on: Authorized officer LS ά Authorized officer Form PCT/RO/134 (July 1992) -91 * INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 136 J) The indications made below relate to the microorganism referred to in the description on page 29 , l __in___e_ 27 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | ] Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40663 C. ADDITIONAL INDICATIONS (leave blank ifna applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are a for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifna applicable) The indications listed belo will be submitted to the International Bureau later (specify the general nature ofthe indications eg., 'Accession Number of Deposit ") For receiving Office use only For International Bureau use only This sheet was received with the international application | | This sheet was received by the International Bureau on: Authorized officer r≠ Authorized officer Form PCT/RO/134 (July 1992) -92- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule \3bis) The indications made below relate to the microorganism referred to in the description on page 34 . l .:in-e__ 3 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40668 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if th nd αύons are na for all deήgnated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifna applicable) The indications listed belowwill be submitted to the International Bureau later (specify the general nature of the indicaύons eg., 'Accesήon Number of Deposit") For receiving Office use only For International Bureau use only This sheet was received with the international application | | This sheet was received by the International Bureau on: Authorized officer Sιø Authorized officer Form PCT/RO/134 (July 1992) -93- INDI CATIONS RELATING TO A DEPOSITED MICROORGANISM A. The indications made below relate to the microorganism referred to in the description on page 36 . line B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40669 C. ADDITIONAL INDICATIONS (leave blank ifna applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are na for all deήgnated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifna applicable) The indications listed belowwill be submitted to the International Bureau later (specify the general nature of 'the indications eg., 'Accesήon Number of Deposit") For International Bureau use only | | This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule libis) For receiving Office use only For International Bureau use only ^ This sheet was received with the international application I j This sheet was received by the International Bureau on: Authorized officer -τ&ptf Authorized officer Form PCr/RO/134 (July 1992) -95- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule llbis) A. The indications made below relate to the microorganism referred to in the description on page 37 , line 1 1 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet j | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Dale of deposit Accession Number 28 June 1994 NCIMB 40659 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This infoπnalion is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are na for att designated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank ifn applicable) The indications listed below will be submitted to the iniemational Bureau later (specify the general nature ofthe indications eg., 'Accesήon Number of Deposit") For International Bureau use only | | This sheet was received by the International Bureau on: Authorized officer -96- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 136ύ) A. The indications made below relate to the microorganism referred to in the description on page 38 , . l_in_._e. 23 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | j Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40664 C. ADDITIONAL INDICATIONS (leave blank ifna applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications arena for att deήgnated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if aa applicable) The indications listed below will be submitted lo the Intemalional Bureau later (specify the general nature of the indicaύons eg., 'Accesήon Number of Deposit") For International Bureau use only | l This sheet was received by the International Bureau on: Authorized officer Form P T/RO/134 (July 1992) -97- INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) A. The indications made below relate to the microorganism referred to in the description on page 40 , line 13 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution The National Collections of Industrial and Marine Bacteria Limited (NCIMB) Address of depositary institution (including ostal code and country) 23 St Machar Drive Aberdeen AB2 1 RY Scotland, UK Date of deposit Accession Number 28 June 1994 NCIMB 40660 C. ADDITIONAL INDICATIONS (leave blank ifna applicable) This information is continued on an additional sheet Q In respect of all designated states in which such action is possible and to the extent that it is legally permissible under the law of the designated state, it is requested that a sample of the deposited micro-organism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. Rule 28(4) EPC, and generally similar provisions mutatis mutandis for any other designated state. D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are na for al! designated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if na applicable) The indications listed belo will be submitted to the International Bureau later (specify the general nature ofthe indications eg., 'Accesήon Number of Deposit') For Internationa] Bureau use only | | This sheet was received by the International Bureau on: Authorized officer Form PCT RO/134 (July 1992)

Claims: CLAIMS 1. A polypeptide which is a water-soluble active derivative of a bacterial bifunctional penicillin binding protein, said penicillin binding protein being bound to the cell membrane when expressed in a bacterial cell and being capable of exhibiting both transglycosylase and transpeptidase activities and said derivative lacking a membrane anchoring sequence but retaining the capability to exhibit one or both of said enzymic activities. 2. A polypeptide according to claim 1 which amino acid sequence is identical to, or substantially similar to, SEQ ID NO: 2, 4, 6, 12 or 13 in the Sequence Listing. 3. A polypeptide which is a transglycosylase deficient derivative of a bacterial bifunctional penicillin binding protein, said penicillin binding protein being bound to the cell membrane when expressed in a bacterial cell and being capable of exhibiting both transglycosylase and transpeptidase activities and said derivative lacking the capability to exhibit transglycosylase activity but retaining the capability to exhibit transpeptidase activity. 4. A polypeptide according to claim 3 wherein the said derivative is lacking transglycosylase activity because of a mutation or deletion in the second conserved region of the gene coding for said polypeptide. 5. A polypeptide according to claim 3 which amino acid sequence is identical to, or substantially similar to, SEQ ID NO: 7, 8, 9, or 10 in the Sequence Listing. 6. A polypeptide according to claim 1 or 3 wherein the bacterial cell is an Escherichia coli cell or a Streptococcus pneumoniae cell. 7. A polypeptide comprising (a) a first polypeptide according to claim 1 or 3; and (b) an additional polypeptide which allows binding to an affinity matrix; there being a cleavage site between said polypeptides. 8. A polypeptide according to claim 7 wherein the additional polypeptide is glutathione-S-transferase or a polypeptide substantially similar to glutathione-S-transferase. 9. A polypeptide according to claim 7 wherein the additional polypeptide is a polypeptide rich in histidine residues. 10. An isolated and purified DNA molecule which has a nucleotide sequence coding for a polypeptide according to claim 1, 3 or 7. 11. A DNA molecule according to claim 10, which nucleotide sequence is identical to, or substantially similar to, SEQ ID NO: 1, 3 or 5 in the Sequence Listing. 12. A replicable expression vector which carries and is capable of mediating the expression of a DNA molecule according to claim 10. 13. A vector according to claim 12 which is the vector pARC0558 (NCIMB No. 40666), pARC0559 (NCIMB No. 40667), pARC0512 (NCIMB No. 40665), pARC0438 (NCIMB No. 40661), pARC0468 (NCIMB No. 40662), pARC0469 (NCIMB No. 40663), pARC0571 (NCIMB No. 40668), pARC0593 (NCIMB No. 40670), pARC0392 (NCIMB No. 40659), pARC0499 (NCIMB No. 40664), or pARC0400 (NCIMB No. 40660). 14. A cell harbouring a vector according to claim 12. 15. A process for production of a polypeptide which is a derivative of penicillin binding protein, comprising growing a cell according to claim 14 in or on a culture medium for expression of the polypeptide and optionally recovering the polypeptide. 16. A process for the production of a water soluble polypeptide according to claim 1 which comprises culturing Escherichia coli cells harbouring an expression vector wherein a DNA coding sequence for said polypeptide is under the control of an " isopropyl thiogalactoside (IPTG) - inducible promoter, said culturing being carried out in the presence of a sub-optimal concentration of IPTG for induction of the said promoter and at a temperature in the range of 20 to 24°C. 17. A method of identifying an antibody capable of binding a bacterial bifunctional penicillin binding protein which includes the step of employing a polypeptide according to claim 1 or 3 in an antibody binding assay and selecting antibodies that bind to the polypeptide. 18. A method of assaying for compounds which bind to a penicillin binding protein, said method comprising (a) contacting a polypeptide according to claim 1, 3 or 7 with a compound to be investigated; and (b) detecting whether said compound binds to the penicillin binding protein. 19. A method of assaying for compounds which bind to a penicillin binding protein, said method comprising (a) culturing cells according to claim 14; (b) lysing the said cells and isolating the crude cell extract; (c) exposing the said cell extract to potential inhibitors of a penicillin binding protein; (d) introducing an agent, known to bind a penicillin binding protein, to the said cell extract; (e) removing the unbound fraction of said agent; and (f) assaying the presence of said agent remaining in the cell extract. 20. A method of assaying for compounds which bind to a penicillin binding protein, said method comprising (a) exposing a polypeptide according to claim 1, 3 or 7, immobilised on a solid support, to a potential inhibitor of a penicillin binding protein; (b) exposing an agent, known to bind a penicillin binding protein, to the immobilised polypeptide; (c) removing the unbound fraction of said agent; and (d) assaying the presence of said agent bound to the immobilised polypeptide. 21. A method of assaying for compounds which bind to a penicillin binding protein, said method comprising (a) exposing a polypeptide according to claim 1, 3 or 7 to a potential inhibitor of a penicillin binding protein; (b) exposing the said polypeptide to an agent, known to bind a penicillin binding protein, which agent is immobilised on a solid support; and (c) assaying the presence of polypeptide bound to the immobilised agent. 22. A method of assaying for compounds which bind to the transglycosylase domain of a penicillin binding protein, said method comprising (a) exposing the transglycosylase domain of a polypeptide according to claim 1 or 7, said polypeptide being immobilised on a solid support, to a potential inhibitor of the transglycosylase activity of a penicillin binding protein; (b) exposing an agent, known to bind the transglycosylase domain of a penicillin binding protein, to the immobilised polypeptide; (c) removing the unbound fraction of said agent; and (d) assaying the presence of said agent bound to the immobilised polypeptide. 23. A method of assaying for compounds which bind to the transglycosylase domain of a penicillin binding protein, said method comprising (a) exposing the transglycosylase domain of a polypeptide according to claim 1 or 7 to a potential inhibitor of a penicillin binding protein; (b) exposing the said polypeptide to an agent, known to bind to the transglycosylase domain of a penicillin binding protein, which agent is immobilised on a solid support; and (c) assaying the presence of polypeptide bound to the immobilised agent. 24. A method according to any one of claims 19 to 23 wherein the agent known to bind a penicillin binding protein is a monoclonal antibody. 25. A method according to any one of claims 19 to 23 wherein the agent known to bind a penicillin binding protein is a labelled antibiotic compound. 26. A method of determining the protein structure of a penicillin binding protein, characterized in that a polypeptide according to claim 1 or 3 is utilized in X-ray crystallography.

Inventors: BALGANESH TANJORE SOUNDARARAJA, TOWN CHRISTINE MARY, BALGANESH, TANJORE, SOUNDARARAJAN, TOWN, CHRISTINE, MARY
Applicants: ASTRA AB, BALGANESH TANJORE SOUNDARARAJA, TOWN CHRISTINE MARY, ASTRA AKTIEBOLAG, BALGANESH, TANJORE, SOUNDARARAJAN, TOWN, CHRISTINE, MARY
Application year: 1995
Main classification: C07K14
IPC codes: C07K14, C07K16, C12N9, C12N15, C12Q1, C12R1, G01N33